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ABSTRACT
Gn1actokinase deficiency .'is an autosomal-recessive inborn error of galactose metabolism
whose major clinical manifestation is the development of cataracts during the first months

of life. This metabolic disorder is caused by defects in the first enzyme of the Leloir
pathway, galactokinase, encoded by the gene GALKJ on chromosome 17q24. Despite the
identification of a number of conserved domains in GALKJ, understanding of the

functional significance of these regions and the molecular basis of the disorder is limited.
This is largeiy due to the rarity of the disease and the fact that the small number of CALK!
mutations identified to-date are confined to individual families, thus precluding extensive
genotype/phenotype correlations.

The current investigation involved an analysis of the GALKI gene in nine patients with
biochemical phenotypes indicative of classical galactokinase deficiency. Sequencing of the
entire coding region, flanking intronic sequence and both the 5' UIR and 3UTR of
CALK! using Dye Tenninator chemist!}' and the ABI377 DNA Analyzer, revealed four

novel mutations in two unrelated patients with galactokinase deficiency. Three of these
were amino acid substitutions: 1569C-->Tin exon 2 (R68C), 7093C-->Tin exon 6 (f288M)
and 7538G-->C in exon 8 (A384P). In addition, a single base deletion was found in exon 5
(2833delC), predicted to result in a shift of the reading frame and a premature termination
codon at posicion 263. Sequence analysis in a third patient detected a 563C_.,A
transversion (P28T), previously identified as a common mutation in six Bulgarian Gypsy
families (Kalaydjieva et al., 1999). The remaining six patients, belonging to socially and
geographitally dispersed Gypsy groups from Spain, Hungaty and Bulgaria were screened
for P28T using a PCR-based Ava! restriction assay. All were homozygous for P28T.
Haplotype analysis established a common origin of the mutation, providing further
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evidence that P28T is a founder mutation among patients with Gypsy edmicity and
signaling the mutation is more widespread than initial indications suggest.

To detennine the carrier frequency and distribution of the P28T mutation, 227 unrelated
individuals originatir.g from various Gypsy groups in Europe, were screened using the A val
assay. Carrier frequency in the Vlax Roma was calculated at 2.7% and 1.8% in Spanish
Gypsies. These results indicate that the prevalence of the P28T mutation warrants further
investigation preceeding the development of newborn screening strategies and dietary
intervention in these groups in a bid to prevent infantile blindness. The findings also allow
the identification of a large sample of carriers suitable for future investigations into
genotype/ phenotype correlations.

Sequence analysis of the GAL/(1 gene in two Afro/Hispanic patients presenting with a rare

atypical phenotype with metabolic symptoms of galactokinase deficiency and normal RBC
galactokinase activity, revealed no plausible disease-causing mutations. In fact, lack of
similarity in the GALKJ gene in both patients, despite sharing a common ethnic

background, suggested exclusion of GAUG in this phenotype.
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CHAPTER!

INTRODUCTION

1.1 Overview
Galac.tokinase deficiency (Gitzelmann, 1965; Gitzelmann, 1967) is an autosomal
recessive inborn error of the first step of the Leloir metabolic pathway through which
galactose enters glycolysis (Frey, 1996). Unlike the .~evere and debilitating symptoms
associated with other forms of galactosemia (Segal & Berry, 1995), the oniy confirmed
symptom of galactokinase deficiency is the development of cataracts (Figure 1. 1). In

homozygotes, these occur within the first weeks to months of life (Levy, Krill, & Beutler,
1972; Beutler et al., 1973; Stambolian, 1988). There is also evidence to suggest that

heterozygote carriers of a deficiency causing allele may be at risk of developing presenile
cataracts (Elman, Miller, & Matalon, 1986; Starnbolian et a!., 1986). The progression to
sight impairment is caused by the accumulation of an alternative product of galactose
metabolism, called galactitot which accumulates within the lens of the eye, ultimately
leading to the rupture and opacification of lens fibers. Fortunately, with early detection and
intervention with a galactose-restricted diet, cataract formation in affected individuals can
be prevented and the pathological changes in the lens can be reversed in some cases
(Olarnbiwonnu, McVie, Ng, Frasier, & Donnell, 1974).
Elucidating the molecular basis underlying galactokinase deficiency began in 1995

with the cloning of the gene GALKI (Starnbolian et al., 1995) and its mapping

to

the

chromosomal location 17q24 (Starnbolian et al., 1995; Kalaydjieva et al., !999). Despite
this, only a limited amount of knowledge exists in regards to the functional organization of
GAL/(1 and conclusive information about the genetic regulation of galactokinase

expression is yet to be fully obtained. Investigations of the molecular basis of galactokinase
deficiency can contribute such informacion. However, these studies are hampered by the
low frequency of the disorder and by the fact that the small number of identified mutations

1

Figure 1.1 "Oil-droplet"cataract in three-month-old child with galactokinase
deficiency. (Source: Campolattaro, 2000)

2

arc confined to single f;unilies, thus precluding reliable genotype-phenotype correlations.
What is known is that the CALK/ gene spans approximately 7.3kb of DNA and is
arranged into 8 cxons that code for a mRNA transcript of 1.35kb {Bergsma ct al., 1996).
Ex on 1 encodes a highly conserved signature sequence common to galactokinascs in a wide
r.mge of orgmisms. The function of this shared region of homology remains unknown, but
mutations within this sequence have been associated with the deficiency phenotype
(Stambolian et al., !995; Kalaydjieva et al., 1999; Kolosha et al., 2000) suggesting that this
area of the gene has a critical role in the normal function of the encoded enzyme. Other
highly conserved areas include exons 3 and 7, which both encode ATP binding motifs
essential for the phosphorylating activity of galactokinase. Again, mutations within these
exons have been identified and linked to the deficiency phenotype (Asada et al., 1999;
Kolosha et al., 2000). The function of the remaining coding regions of GALKI and how
they affect the activity of the galactokinase protein remain to be determined. Mutation
analysis of DNA samples from galactokinase-deficient individuals and comparison with the
wild-type allele, offers a useful tool for elucidating the role that regions within the gene play

in the structure and function of the encoded enzyme.
An opportUnity to add to the known mutations of GALKI and the possibility of
gaining an understanding of the regulatory mechanism of the gene has arisen as a result of
collaboration between the Centre for Human Genetics at Edith Cowan University, the
Department of Pediatrics at Harvard University Medical School, USA, the University
Children's Hospital in Zurich, Switzerland, the Department of Pediatrics at the Medical
School in Szeged, Hungary and the Insritut Bioquimica Clinica in Barcelona, Spain. The aim
is to sequence the GALJ(J gene in patients who exhibit biochemical findings typical of
galactokinase deficiency. This analysis may provide new information about the molecular
pathology underlying the condition and about the function of the encoded protein domains.
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A number of these patients are of Gypsy ori&ins. Analysis of the GALKI gene in such
individuals wi11 provide information on the homo/heterogeneity of the molecular basis of
galactokinase deficiency in this population, known to have a high frequency of the disorder.
The identification of a common mutation, P28T (Kalaydjicva ct al., 1999) will allow a study
of the history of the mutation. It will also open the way to the detection of large numbers of
genetically homogenous affected individuals and carriers which, in tum, will allow future
studies of genotype-phenotype correlation and of the role of GALKl in presentle cataracts.
In addition to these individuals, a new sample of patients has been identified who
share elevated plasma galactose levels and galactitol production analogous to the deficiency
phenotype, yet whose biochemical assays reveal no discernible loss of function to any of the
red blood cell enzymes involved in the Leloir pathway. These clinical observations question
existing concepts of galactose metabolism) in particular casting doubt upon the presumption
that measurement of erythrocyte enzyme expression reflects adequately the phenotype. The
possibility that multiple forms of the galactokinase enzyme exist is supported by age and
tissue-related differences in enzyme expression levels (Ng, Donnel, & Bergren, 1965; ShinBuerhring, Beier, Tan, Osang, & Schaub, 1977), variation in kinetic propenies between
galactokinase from adult and fetal/newborn sources (Cuatrecasus & Segal, 1965; Mathai &
Beutler, 1967; Magnani, Cucchiarini, Stocchi, Dacha, & Fornaini, 1982b) and discrepancies
between biochemical phenotype and genotype in some affected individuals (Kalaydjieva et
al., 1999).
Whether these observations can be attributed to two forms of galactokinase encoded
by separate genes, or reflect post-translational modifications, or alternative transcripts of
the same gene, remains to be seen. The study of the GALKI gene in patient:. with
metabolic e\idence of galactokinase deficiency yet normal RBC enzyme activity, may
provide an answer to some of these questions.

4

1.2 Significance of the study
l11e study of the molecular basis of galactokinase deficiency is important for a number of
reasons including;

1.2.1 Adding knowledge to the structure and function ofGALK1
An important outcome from this investigation is the possibility of adding to the
limited knowledge concerning the molecular organization and function of GALKI.
While some aspects of the coding region of GALKJ are known, the role of other

regions within the gene and how they detennine the structure and hence function
of the enzyme remain relatively unknown. The identification of mutations and

correlation with the disease phenotype will provide information mto the
importance of these genomic areas to normal galacrokinase expression.

1.2.2 Understanding the mechanisms of spread of common founder
mutation(s) in GALK1 and identification of high-risk groups
There is evidence suggesting wide ethnic variation in the incidence of galactokinase
deficiency, with a higher frequency among subjects of Gypsy origin. Investigations
into the molecuhr epidemiology of the disorder will provide an insight into the
nature and mechanisms of spread of the underlying mutations, and will identify the
Gypsy populations where early neonatal detection and dietary treatment will
prevent childhood blindness.

1.2.3 Possible links to presenile cataract formation
Further benefits derived from the understanding of galactokinase expression and
funr.r.ional domains would not only be limited to homozygote sufferers. There is
also evidence to suggest that heterozygote carriers of a deficiency·causing allele may
be at risk of developing presenile cataracts (Starnbolian et al., 1986). When we
consider that heterozygote frequency for galactokinase deficiency has been

5

estimated to fall within the ranges of approximately 1 in 100 (Mayes & Guthrie,
1968) to 1 in 300 individuals (Tedesco et al., 1975), the relationship between carriers
and presenile catarad formation may point towards partial galactokinase deficiency
as a significant contributor to the overall frequency of cataract cases in the wider
population. Thus, understanding the genetic regulation of galactokinase expression
would have great implications in the development of intervention strategies, in
particular the extent that pre~clinical testing and dietary measures would need to be
taken in susceptible individuals.

1.3 Research ainlS
The aims of the research consist of the following:
1.

To study the molecular basis of classical galactokinase deficiency through;
a) Identification of novel mutations and polymorphism in the GAL!(] gene.
b) Analysis of the history and frequency of common mutation{s) in the
GALKI gene.

ii. To investigate the role of CALK/ in the development of an atypical phenorype

with metabolic symptoms of galactokinase deficiency and normal RBC activity.

6

1.4 Operational terms and definitions

A, C, T, G

Adenine, Cytosine, Thymine, Guanine

ABI

Applied Biosystcms I ncorporatcd

A1P

Adenosine triphosphate

Bp

Base pairs

eDNA

Complimentary deoxyribonucleic acid

CpG

Dinucleotide with a cytosine at the 5' end connected by a phosphodiester bond
to a guanine at the 3' end. Mutational hotspot due the susceptibility of cytosine
to undergo methylation and deamination to thymine.

Da

Daltons

ddNTPs

Dideoxynucleotide triphosphates

DNA

Deoxyribonucleic acid

dNIPs

Deoxynucleotide triphosphates

GALKl

Galactokinase gene

kb

Kilo bases

KM

Michaelis constant

mRNA

Messenger ribonucleic acid

MgCI2

Magnesium chloride

mM

Millimolar (10 _,)

nM

Nanomole (10 -~

PCR

Polymerase chain reaction

RBCs

Red Blood Cells

RNA

Ribonucleic acid

S'UIR

5' Untranslated region

3'UIR

3' Untranslated region

7

CHAPTER2

LITERATURE REVIEW

2.1 Galactokinase
2.1.1 Galactokinase and the Leloir pathway
The function of the Leloir pathway of metabolism is to convert galactose into
glucose-6-phosphate in preparation for utilization in glycolysis,

glycogenesis or

incorporation into nomtal cellular complex carbohydrates (Frey, 1996). In mammals, the
main dietmy source of galactose is the hydrolytic breakdown of milk-sugar into the

monosaccharides glucose and galactose. Galactose then enters the Leloir pathway where it

undergoes phosphorylation by galactokinase to fonn galactose·l·phosphate (Figure 2.1).

Gak.wse·l-p/nsp:ue
1f1il:#rran.ferase

Galacwkinase

Galactose

(

") ., Ga1actose-1-phosphate

ATP ADP

~ Gluctose-6-phosphate

UDP-glu

'!,..__/

UDP-G.ll

Figure 2.1 Role of galactokinase in the Leloir pathway
The function and expression of this enzyme has been characterized in a number of

organisms, including bacteria (Wilson & Hogness, 1969), mice (Ai et al., 1995),

rat

(Cuatrecasus & Segal, 1965), porcine liver (Ballard, !966), as wetl as various human tissues
including etythrocytes, leukocytes, placenta (Srivastava, Blume, Van Loon, & Beutler,

1972) and fibroblasts (Friedman, Yarkin, & Merril, 1974). The most significant galactose
conversion occurs within the liver, where expression levels of galactokinase are
approximately 50 times higher than those in other tissue sources (Shin-Buerhring, Beier,

Tan, Osang, & Schaub, 1977). Uptake of galactose from the bloodstream by the liver is a
highly efficient process (Goresky, Bach, & Nadeau, 1973) mediated by two factors, firstly,
8

the movement of galactose across the hepatocyte membrane by the presence of GLVT2
transporters {Burchell, 1994) and secondly, its conversion to galactosc-1-phosphate by
ga1actokinase. Such is the efficiency of this process, that galactose has been used to
measure hepatic function and blood flow in physiological studies (Henderson & Hanna,
1983). The other significant site of net removal and utilization of galactose is in the
erythrocyte. Here, galactose is used as an energy source via its conversion to glucose-6-

phosphate and entry into the glycolytic pathway. Although galactokinase from both
erythrocytes and liver catalyzes the same reaction} the utilization of the end metabolic
product differs. It is not surprising therefore that a number of differences exist berween
the levels of activity and kinetic properties of the liver and RBC enzyme, some of which
have been interpreted as evidence of the existence of multiple forms of the enzyme

(Cuatrecasus & Segal, 1965; Ng et al., 1965; Mathai &Beutler 1967).
2.1.2

Age and tissue-related differences in gttlactokinttse expression
Measurement of galactokinase in individuals of v.ulous ages suggests that enzyme

activity is considerably higher during infancy than later in life (Ng et al., 1965). In fact, up to
a period of three years after binh, galactokinase activity is nearly 3 times higher than that of
older children and adults. This may in part reflect changes from the early nutritional intake
of galactose derived from breast milk to a more varied diet in adulthood. The high
expression of galactokinase in infancy may reflect the important role galactose may have as
an energy source in early development and growth.
Galactokinase is found to differ between fetal liver} kidney, lung, spleen, muscle and

brain in regards to substrate afftnity as well as duration and degree of expression (ShinBuerhring et al., 1977). Enzyme activity in liver increases in a linear progression with

gestational age, reaching its maximal peak by 28 weeks. Expression within the brain
however, remains constant for the first 5 months of prenatal development before increasing
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to preterm levels. These observations suggest that independent or tissue·specific regulation

of galactok.in;lSe expression may be occurring between these tissue sources based upon the
substrate needs of e;Kh tissue type.
Other tissue differences are noted when galactok.inase isolated from placenta is

compared to both the livec and erythrocyte enzyme (Table 2.1). These differences refer

to

kinetic properties of the enzyme, as well as to the physical characteristics of the protein.

Table 2.1
Galactokinase Properties in Various Tissue

Km galactose
KmATP
Inhibition by G-1-P
~
b
c

2501JM

100-150 ~M

JOO~M

200-SOO~M

High

nil

Fetal/newborn> adult
Fetal/newborn> adult
Fetal/newborn> adult

Srivastava rt al.. (1972)

Blume and Beuder (1971)
Cuatrecasas and Segal (1965)

Note. Liver properties measured in rat

Other differences are noted in the functional role of galactokinase. It has been
suggested that galactokinase

in

liver can act in a rate·limiting manner that prevents the

toxic accumulation of galactose-1-phosphate, implicated in the severe pathological

symptoms observed in other defects of galactose metabolism (Segal & Beny, 1995).
Evidence supporting this function comes from sustained galactose loading in rat liver

(Rogers, Bovee, Saunders, & Segal, 1989) and human liver-derived cell lines (Davit-Spraul,
Pourci, Soni, & Lemonnier, 1994), where galactokinase activity declines in response to

chronic overloading as a result of the inhibition by galactose-1-phosphate. This rate-limiting
role is not evident in human erythrocytes (Mathai & Beutler, 1967) suggesting that this
function is limited to the liver form of the enzyme.

The rate-limiting role of liver

galactokinase is age-dependent (Cuatrec.sus & Segal, 1965), with fetal galactokinase
inhibited by galactose-1-phosphate more than the adult enzyme. Other differences noted in
10

this investigation include greater stability and a ga1actosc KM approximately 4 times higher
in fetal galactokin•tse compared to the adult enzyme.
Further evidence of age-related differences in kinetic properties comes from
comparative studies between adult and fetal erythrocytes. Mathai and Beutler (1967) found

slight but statistically significant evidence for a fetal RBC. galactokinase with higher KM for
galactose than that derived from adult sources. This observation remains when the agerelated differences in erythrocyte composition are accounted for (Magnani et al., 1982b),
such as the separation of both fetal and adult red blood cells into fractions of different
mean ages by density gradient ultracentrifugation prior to measuring galactokinase activity.
This technique offers a more accurate indication of enzyme activity by accounting for the
inverse relationship between erythrocyte life-span and enzyme levels. Funher findings by
Magnani et al. (1982b) include a fetal erythrocyte galacrokinase with specific activity three
times higher than the adult enzyme (Table 2.2) and displaying considerably greater
thermostability than the galactokinase derived from adult erythrocytes.
Table 2.2
Properties of Galactokinase in Adult and Fetal EQ'!hrocytes

Molecular weight
Specific activity
KM galactose
KMATP

Erythrocyte galactokinase•
Fetal
Adult
48 000
48 000
39.5 mU/gHb
12.7 mU/gHb
215 ~M
113 ~M
400~M
320 ~M

• Magnani et a!. (1982b)

2.1.3 Differenc., in the physical properties of the enzyme
Differences in the physical properties of galactokinase are also known to exist.
Srivastava et a!. (1972) describe a placental galactokinase with a larger molecular weight
than that derived from adult erythrocytes. Tooesco et a!. (1973) provide a description of
erythrncyte galactokinase isolated from one individual that has higher electrophoretic
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mobility omd higher enzyme activity than that found in erythrocytes from adult controls.
The kinetic properties are similar to placental galactokinase, suggesting a persistent
expression of a fetal fonn of the enzyme.
Conclusive information about the differences in molecular structure that would
account for these observations is lacking. An early investigation into the physical makeup
of galactokinase derived from erythrocytes suggested a dimeric structure consisting of two

monomers of molecular weights 25 OOODa to 27 OOODa (Blume & Beutler, 1971). A
succeeding study, using a much more effective technique of protein purification, found no
evidence for a dimeric structUre in either erythrocytes or placental ga1actok.inase

(Starnbolian, Scarpino-Myers, & Harris, 1985). In fact, the latter study reports the
monomeric galactokinase from both sources as having a molecular weight of approximately

38 OOODa, significantly lower than previously thought (Srivastava eta!., 1972). This, again,
contrasts with an analysis of eDNA derived from osteoclastoma and T-ee!! eDNA libraries
(Starnbolian eta!., 1995): based upon the nucleotide sequence, the molecular weight of the
encoded galactokinase from these sources is predicted to be 42 271 Da.

2.1.4.41/e/ic variation and genotype/phenotype differences
Allelic variations from the recognized wild-type GKA/GKA genotype have been
identified and point towards polymorphism between populations. The Philadelphia variant,
GK, (Tedesco et a!., 1977) is found in high frequency amongst the African/American

population {Soni, Brivet, Blanc, Jaeger, & Lemonnier, 1988) and causes reduced
galactokinase activity in RBCs, yet normal levels of enzyme e."Xpression and function in
leukocytes. Another suggested allelic variation is the Urbina variant {Magnani, G.tcchiarini,

Dacha, & Fomaini, 1982a). This galacto kinase has reduced catalytic properties, decreased
in'Uiw stability and a lower KM for ATPMg'" than the enzyme encoded by both the wild-

type, GKA and some deficiency-causing; GKc alleles. It is possible that the degree and
range of allelic variants may in fact be more widespread than those already characterized.
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Other genotype/ phenotype discrepancies have been detected that may support
heterogeneity in galactokinase expression. An interesting observation in a kindred studied

by Kalaydjieva ct al. (1999) was the biochemical findings of an individual homozygous for
the P28T mutation who displayed intermediate erythrocyte galactokinase activity analogous
to a heterozygote cotrrier. This particular individual reported a history of juvenile cataracts
suggesting a lack of enzyme activity at an early age. Why this person is now expressing
galactokinase despite being homozygous for the deficiency causing mutation is unclear. It
has been suggested that this intermediate activity may represent expression of an adult form
of the enzyme. Whether this expression is due to the existence of another gene or agerelated differences ir. the expression of the GALKJ encoded protein is unknown.

It remains unclear whether the age and tissue-related differences in levels of activity,
kinetic properties and physical characteristics are the product of differences in the
regulation of expression and/or post-translational modification of a single gene product or
whether they result from the existence of more than one galactokinase gene.

2.2

Galactokinase Deficiency

2.2.1 Clinical synopsis and symptoms
In 1933 Fanconi, as cited in Gitzelmann (1965), first described "galactose diabetes", a
term used to denote an aberration of galactose metabolism, whose only symptom was the
development of early-onset cataracts. The exact enzyme defect was not confirmed until

Gitzelmann (1965) measured erythrocyte galactokinase in a patient first diagnosed by
Fanconi, and found negligible enzyme activity. It is now recognized that deficiency of
galactokinase can cause the formation of juvenile cataracts in homozygotes.
Cataracts remain the only confirmed symptom of the disorder, despite isolated

reports of neurological impairment (Pickering & Howell, 1972) hepatosplenomegaly
(fhalhammer, Gitzelmann, & Pantlitschko, 1968), neurofibromatosis (Gitzelmann, 1965)
and pseudotumor cerebri {Litman, Kanter & Finberg, 1975).
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Biochemical assays in galactokinase·dcficicnt individuals reveal elevated plasma levels
of galactose, called hypcrgalactosernia, the presence of unrnetabolized galactose in the urine,
known as galactosuria, and the presence of a sugar poly! in both urine and tissue called
galactitol (Gitzelmann & Hansen, 1980). It is galactitol, the product of an alternative
pathway of galactose metabolism, that is implicated in causing the degenerative changes to
the lens of the eye. The pathological progression to cataract formation in humans occurs
due to the influence of a number of interacting processes initiated by high intake of dietary
galactose. When galactose levels are elevated, aldose reductase within the lens of the eye
catalyzes the conversion of galactose to galac.titol. Galactitol cannot be further metabolized
by the body and as a result accumulates within the lens. This causes osmotic changes in the
optic fluid, causing the disruption of cell membranes and ultimately the opacification of lens
fibres. This mechanism is evident in galactokinase·deficient strains of mice transfected with
the human aldose reductase (hAR) gene (Ai et al., 2000). These transgenic mice, when fed a
high galactose diet rapidly develop cataracts. This is in contrast to wild·type galactokinase·
deficient mice where aldose reductase activity within the lens is negligible. These
observations suggest that it is the high intake of galactose, in conjunction with a deficiency

in galactokinase, on a background of aldose reductase expression in the lens, that results in
the development of cataracts.

2.2.2 Epidemiology
The I".mge and incidence of galactokinase deficiency (fable 2.3) varies widely berween
populations. Across USA, Japan and Western Europe newborn screening has only detected
6 cases amongst 6 million births (Levy, 1980). By contrast, data from Austria, Germany and
Bulgaria suggest a higher incidence ranging from approximately 1: 52 000 to 1: 157 000
births {Gitzelmann & Hansen, 1980; Kalaydjieva et a!., 1999). The highest frequency has
been found among the Vlax Roma, with one affected homozygote per 1 in 1600-2500
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binhs. The high incidence has been attributed to a founder mutation segregating in this

isolate {Kalaydjieva eta!., 1999).

Table 2.3
Variation in Incidence and Allele Frequency
Incidence/Frequency

Region/Population

Source

Homozygotes
I d 000000
1 ' 157 000
L 153 000
1,52000
1 ' 1600. 1, 2500

USA, Asia, Europe
Germany

Levy (1980)
Gitzelnunn & Haruen (1980)
Gitzelmann & Hansen (1980)

Austria
Bulgaria
VlaxRoma

KalaydjiP.va et al .. (1999)
Kalaydjieva et al .. (1999)

Caucasian
Caucasian
Caucasian/Nth American

Gitzelmmn (1967)
Mayes & Guthrie (1968)
Ted,co e1 ol .. (1975)

Heterozygotes

'so

1
1' 107

LJ04

Early studies that measure erythrocyte galactokinase activity in adults suggest that the
heterozygote carrier frequency of a deficiency allele falls in the range between 1 in 50

(Gitzelmann, 1967) to 1 in approximately 100 individuals {Mayes & Guthrie, 1968). The
predicted frequency of affected births from these estimates is considerably higher than that
actually detected by newborn screening programs.
The above studit:s are based on the detection of heterozygous earners by
measurement of RBC enzyme activity, with some inherent problems. On one hand, enzyme
activity fluctuates widely and is an unreliable indicator of carrier status. Furthermore, the
results can be affected by variations in methodology, increasing further the error range. In
addition, it is unclear to what extent RBC activity reflects the organism's ability to

n.etabolize galactose.
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It is possible that other factors may be involved in this discrepancy, including
miscalculation of heterozygote frequency due to the presence of allelic variants of
galactokinase. The aforementioned Philadelphia variant (Section 2.1.4) is one such allele in
the African/American population that causes a reduction in erythrocyte activity yet normal
expression in other tissue sources (Tedesco et al., 1973; Tedesco et al., 1975). No
detrimental effects are associated with this genotype. It is possible that early studies that
relied upon erythrocyte assay to detennine galactokinase activity may have inadvertently
measured similar allelic variants unknown at the time of the study, therefore overestimating
heterozygote frequencies for the deficiency allele.
Other considerations that may account for these discrepancies include the possibility
of the existence of two f01ms of the galactokinase enzyme, one expressed during early

development and childhood, the other during adulthood. Therefore if heterozygote
frequencies have been calculated from adult samples based upon erythrocyte expression
alone, the enzyme measured may not be the galactokinase involved in the infantile
deficiency. Given the differences in galactokinase properties and expression patterns as a

function of age {Section 2.1.2), this second explanation appears plausible.

2.2.3 Possible role of galactokinase deficiency in presenile cataract formation
The pathological progression to cataract formation may not be restricted to
homozygote sufferers. It has been suggested that heterozygote carriers of a deficiency allele

may be at risk of developing cataracts during the 2"' to s•h decade of life {Starnbolian et a!.,
1986). Other studies fmd no such relationship {Magnani, Cucchiarini, Stocchi, & Dacha,
1983). The reasons for these_discrepant findings :u-c unclear. One possible explanation is
differences in galactose content in the diet, where a high intake can contribute to cataract

formation. This may be due to the fact that erythrocyte galactokinase assay of individuals
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carrying only one functioning allele reveal galactokinase activity at approximately 50% of
normal {Sit:nnann & Kaloud, 1976). Thus, sustained levels of galactose in the diet may
overload the net conversion of galactose to ga1actosc-1-phosphate, in turn promoting the
formation of galactitol and with it the disrupriom to lens integrity.
The effects of increased dietary ima1~e of galactose coupled with reduced
galactokinase activity and its role in cataract fonnation is also supponed in an investigation

of maternal enzyme levels during pregnancy (Harley, Mutton, Irvine, & Gupta, 1974). llis
study found that galactok.inase was significantly reduced in mothers whose children have
congenital cataracts, despite these children having normal erythrocyte enzyme expression
levels and activity. Tills suggests that marginal maternal deficiency of galactokinase coupled

with an increase in lactose intake during pregnancy may exceed the maternal ability to
effectively metabolize galactose.
The proposed link between galactok.inase deficiency and presenile cataract formation
has never received solid support. Mutation detection would offer a much more direct
approach to the identification of carriers, however this has been hampered by the low
incidence of the disorder and the private nature of most of the GALKJ mutations identified

thus far {Section 2.4). It is the through the identification of populations at high risk, where a
single common founder mutation ocrurs at a high frequency that will allow a large number

of carriers to be identified. The relationship between pattial galactokinase deficiency and
presenile cataract could thus be investigated.

2.3 The GALKJ gene: Localization and Structure

23.1 Localization
The localization of the gene encoding galactokinase on the long arm of chromosome
17 was first determined using somatic cell hybridization by Elsevier eta!. {1974). In 1995,
physical Imppingusing fluorescent in-situ hybridization (FISH) ?laced the GALKI gene on

17

band 17q24 (St.unbolim et .U., 1995). Further refinement of this position to within a 1 eM
distance wo1s achieved using linkage ana1ysis and radiation hybrid mapping by Kalaydjicva ct
al. (1999). The earlier identification in 1992, of a eDNA from a gene called GK2 wl'ich
shared similar characteristics to galactokinase, questioned the exact chromosomal
assignment

of the

galactokinase gene (Lee, Peterson, Caiman, Herskowitz, & O'Dunnell,

1992). However a succeeding study (Pastuszak, ODonnell & Elbein, 1996) found that
.Uthough the protein encoded by GK2 could phosphorylate g.Uactose, this could only occur
when the substrate was present in millimolar concentrations. Instead, GK2's major role is

to phosphorylate N-acetylgalactosamine, a component of complex carbohydrates found in
eukruyotic cells.

2.3.2 Characterization
The isolation of GALKI eDNA by Stambolian et .U. (1995) was initi.Uiy based on
comparisons of the sequences of peptide fragments derived from human placental
galactokinase, to a number of eDNA libraries and expressed sequence tags (ESTs).
Significant similarities were found in two human eDNA clones. The analysis of the

nucleotide sequence of these cDNAs predicted a mRNA product of approximately 1350
nucleotides. Further studies reve.Ued the full-length genomic organization of GALKJ
(Bergsma et .U., 1996). The gene spans approximately 7.3kb of DNA and is made up of 8
exons coding for a mRNA transcript of 1358 nucleotides, in accordance with the transcript

size isolated earlier by Stambolian et .U. (1995).
Desrite these an.Uyses, understo~ding of the function.U organization of the GALKI
gene is limiteri to only a small number of domains (Figure 2.2). Exon I contains a highly
conserved signature sequence common to a wide range of organisms including bacteria,
yeast (Stambolian et .U., 1995) mice (Ai et .U., 1995) and humans. The function of this

shared region of homology remains unknown but a number of mutations within this

domain have been associated with the deficiency phenotype (Stambolian et a!., 199 5;
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Kahtydjieva et al., 1999; Kolosha et al., 2000), suggesting that this area of the gene has a

critical role in the normal functioning of the encoded enzyme. Other conserved areas

include exons 3 and 7, both encoding ATP-binding motifs essential for the phosphorylating
activity of galactokinase.
The other remaining area of the human GALKJ gene characterized, includes a 72bp
sequence of the last exon which has been found to encode the carboxyl tcnninus of the
galactokinase protein (Bergsma, et al., 1996).
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2.3.3

5'UTR and promoter region
The promoter region of GA LK I is found approximately 370bp upstream of ex on 1

(Bergsma eta!., 1996) and lacks the TATA and CCAAT box motifs thought necessary for
accurate mRNA initiation (Strachan & Read, 1998). Instead, the S'UlR is characterized by a

polymerase II promoter with a high GC content, indicative of potential binding sites for the
Spl transcription factor (fjian, 1995). In fact, three sites for Spl arc recognized. In
addition, the S'UIR contains a number of possible transcription stan sites downstream of
the promoter region, positioned between 21 and 61 hp upstream of the first exon (Figure

2.3). The presence of these multiple mRNA stan sites is attributed to the lack ofTATA and
CCAAT motifs. An interesting point to make about this observation is that Bergsma et

al. 's

{1996) description of these multiple start sites was derived from the 5' ends of mRNA
transcripts isolated from placental tissue. It is possible that these start sites are unique for
the galactokinase produced in this tissue and may not be indicative of the transcriptional
origin of GALKJ mRNA in other tissue sources. This factor may partly account for the
different physical and kinetic propenies evident between placental and liver forms cf the
enzyme.

Discrepancies exist in the nucleotide sequence of the non·coding regions of GALKJ
reported by Asada et al. {1999) and by Bergsma et al. (1996). Three nucleotide differences
have been found in the S'UIR of GALK.l among a small sample of Japanese and Caucasian
subjects representing both wild type and deficiency phenotypes. This area, although not
transcribed, has been shown to affect and influence the transcriptional activities of genes
(Cooper, Kraw=d<, & Antonarakis, 1995). These differences may reflect polymorphisms,
however given the limited number of sannples analyzed, this possibility is unclear. Other
discrepancies noted by Asada et al. {1999) include several nucleotide re-arrangements in
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introns 1, 2 and 5. A 20bp tandem repeat was also found in intron 5 that had not been
previously detected by Bergsma et al. (1996). As with th e differences noted in the 5'UTR, it
couJd not be confirmed whether these are the result of polymo rphisms unique to the
population studied or in fact reflect errors in the published sequence.

5'
-481 CTGATG,-\CCT

CTCAC:\GCTG

CTGGCCCTGG GGACCTAGGG GATCCCTTTG

-431 GGfu-\.TCCCAG

GTCfu-\CCGGG

TGCC;\GCTCC ATTGCTCTGG CTGTGTGGGT

-381 GGTGGTGGGT GGTG'"\GGCAC ATAGAAAGTC ACCAGCGCCA GGGAAGGGCA
-331 GCTCAGAAAT

CCTGGTCATG CCAAGTGCCA CTCAGGGCTA TTCTCACTCT
.G.
-281 AGTGAGTGCT CATTGGTTCT TCCCGAAGTC CAGAGGGAAG GAC \ CCATCG
-231 GGGGCGCTGT ATCCCACCCG GCACCATTAG CCCCTGCCAC

CCACCACCCA

-181 GCAGCTGGAT TCCCACGGGA GTTGCGGGTG GGGGCGGAAC CGGCTGAGGT
-131 CTGGGGGCGG GGCGTCCGGG CGCGGGGCGG GGCT GGCGGG AATGTGCGCA
~

-81 CCCCCGCGCG

~

. ..

GGGCTCCTCC

CGAGCATCCC

-31 GAGCAfCT~T GCAGAGCTGC AGGCGCGCGT

•

.A.
G

£

.. ..

..
........
cl

GCGCCGACGG GGCTGTGCCG
ATG GCT GCT TTG AGA
met

ala

ala
leu
exon 1

arg

multiple transcription start sites
binding sequence for Sp1 transcription factor
Bold face type denotes polymerase II promoter sequence
Base discrepancy detected by Asada et al.. (1999)

Figure 2.3 GALK1 5'UTR•
•

Adapted from Bergsma et al.. (1996)
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2.4

Mutations in GALKI associated with enzyme deficiency
Due to the low incidence of galactokinase deficiency, only a small number of patients

have been available for mutation analysis, therefore the number of mutations identified and
characterized in the GALKI gene remains small (Figure 2.4). To-date, only 20 mutations
have been reported among 32 individuals with gal.actokinase deficiency {Stambolian et al.,
1995; Kalaydjieva et al., 1999; Asada et al., 1999 & Kolosha et al., 2000). The origins and
ethnicity of these patients are diverse and include individuals of European/American,
Japanese, Turkish, Afro/ American, Hispanic, German, Swiss, Costa Rican and Vlax Gyfey"
descent. The majority of these mutations are confined to individual families and as a result
hamper meaningful genotype-phenotype correlations and also impede research into the link
between partial deficiency and presenile catilract formation. The private nature of these
mutations also determines that effective mutation testing in most populations for both
newborn screening and mass detection of carriers is not feasible.
Mutations published to-date are shown in Table 2.4 and include 9 missense mutations
and 9 truncating mutations arising from insertions, deletions and nonsense stop signals.
Five missense mutations occur in exon 1. Th.:.se include a G-). T transition at nucleotide
position 3, which changes the initiating AUG codon to AW, causing a methionine to
isoleucine substitution (Kolosha et al., 2000). This causes translation to begin at the second
AUG codon resulting in a galactokinase protein lacking the first 54 annino acids. The
second missense mutation in exon 1 is a

82C~ A

transversion causing a proline to

threonine amino·acid change at codon 28. This substitution was identified as the founder
mutation causing galactokinase deficiency within the Vlax Roma population (Kalaydjieva et
al., 1999). This missense substitution occurs in close proximity to a 94G~A transition that
results in a V32M change, reported in an unrelated sample (Stambolian et a!., 1995).
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Table 2.4
Mutations Identified in GA LKJ
Mubtion type

St:unbolian et ..!. (1995)

Nucleotide

Missense
Nonsense

94A~G

Kab.ydjieva et al. (1999)
Asada et ..!. (1999)

Result

238G--.T

V32M
QBOX

Stop codon...... truncated protein

Missense

82C--.A

P28T

Disrupts loop-beta tum motif

Missense
Missense

766C--.T

R256W
T344M
G349S
163
201

Not characterized
Occurs at ATP binding site II
Occurs at ATP binding site II
In frame nonsense codon
In frame nonsense codon

Deletion
Deletion

1031C-+G
1045G---ioA
410deiG
509-SlOdeiGT

Insertion
Missense

228ins 67bp

77

3G-+T

Insertion

1012insG

Nonsense
Ddetion
Missense
Insertion
Missense
Missense
Insertion

1144C--->T
761deiG
106G--->C

Mll
338
Q382X
254
G36R
204
H44Y
G346S
94

Missense

Kolosha et ..!. (2000)

Amino acid

610insG

llOC--->T
1036G-+A
280insACT=

Disrupts loop-beta tum motif

Frameshift at amino acid 77
Protein lacks first 54 amino acids
Frameshift at amino acid 338
Stop codon--. truncated protein
Frameshift at amino acid 254
Occurs near conserved region
Stop codon-.. truncated protein
Occurs near conserved region

Occurs at ATP binding site II
Frameshift at amino acid 94

Two other missense mutations occur in exon 1 and include a 106G~C transversion
causing a G36R substitution, while the other is a 130C4>T transition resulting in a H44Y
amino acid change {Kolosha et al., 2000). Three missense mutations, R256W, T344M and
G348S (Asada et al., 1999) occur at CpG nucleotides, which are known mutational hotspots
(Cooper et al., 1995). One of these, R256W caused by a 766C~T transition, is found in
exon 5 (Asada et al., 1999). This mutation does not occur within a recognized conserved
motif and its effects upon the structure of the protein were not investigated. Both the
1031C~G transversion which

prtxhces the T344M amino acid change and tbe

1045G~A

transition which causes the G349S substitution, occur in the ATP-binding site sequence in
exon 7. An additional missense mutation has also been found to occur in this region and is
a G346S substitution resulting from a 1036G~A base change {Kolosha et al., 2000).
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A nwnber of truncating mutations have also been reported in the GALKJ gene. Two
of these, ESOX and Q382X, are the result of nucleotide changes. ESOX results from a
238G~ T

transversion in exon 2, which creates a termination codon producing a truncated

galactokinase protein of only 79 amino acids (Starnbolian ct al., 1995). The Q382X

nonsense mutation results from a 1144C-1> T transition in exon 8, which is known to
encode the carboxyl terminus of the enzyme. As a result of this premature termination
codon, the enzyme was predirted to lack a number of C-terminal amino acids. Subsequent
expression analysis in oocytes suggested that low measured galartokinase activity was
attributed to the 1144C->T substitution. This finding suggests that the carboxyterminus of

the protein is essential for normal galactokinase function.
The remaining truncating mutat1.ons result from 3 deletions, 4lodelC, 509-SlOdelGT,
(Asada et al., 1999) and 761deiG (Kolosha et al., 2000) and 3 insettions, 610insG,
280insACfGCCC and 1012insG (Kolosha et al., 2000). All result in frarneshifts that
produce a truncated protein. The duplication of a 67bp sequence of the 5' end of exon 2
and 5bps of the adjoining intron (288ins67bp) found in one individual was found to cause

an additional 5' splice acceptor site (K.olosha et al., 2000). This insertion results in the
removal of the normal 5' end of exon 2 during splicing, producing a partial and thus
nonfunctional galactokinase transcript.
Mutations characterized within the GALI\1 gene have pointed towards the functional
significance that particular regions may have upon the encoded protein. The clustering of
nucleotide aberrations within highly conserved areas of the GALI\1 gene or recognized
functional motifs, highlight the impottance that each region has in the normal activity of the
encoded galactokinase. Five missense mutations, Mil, P28T, V32M, G36R and H44Y
occur in exon I and of these, both G36R and H44Y reside within the highly conserved

galaaokinase signature domain. Their effects upon the secondary structure of the protein
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are not reponed, however it is likely that they interfere with an unknown function that
seems critical for normal galactokinase activity. The two missense mutations, P28T and
V32M, occur in close proximity to this signature sequence. In fact, computer models of the
protein configuration

c~used

by both P28T and V32M, reveal similar secondary structural

changes that interfere with a loop-beta tum motif immediately preceding the conserved

domain (Kalaydjieva et al., 1999). The fact that the majority of the missense mutations
found in the GALl(] gene cluster within exon I, which encodes the highly conserved
fingerprint motif, suggest this region plays a crucial role in the normal activity of the
enzyme.
Another clustering of three missense mutations and one insenion occurs in the

second A1P-binding motif in exon 7. Three of these, T344M, G346 and G349S, occur

within a 5 codon span, suggesting a small region exists within this domain that is critic.U for
nonnal function. The fact that these are missense mutations, may reflect a critical
conformational dependence in order for normal ATP binding to occur in the encoded
protein.

To-date, only three mutations (P28T, Q382X and G349S) have been reported to
occur in multiple individuals with galactokinase deficiency. The G349S substitution has
been found in the heterozygous state in two galactokinase-deficient individuals. These

patients differ in ethnic origin: one is German (Kolosha et al., 2000) and the other Japanese
(Asada et al., 1999}, suggesting this mutation is a reccurence of the amino acid substitution

at the same codon. The remaining two mutations, P28T and Q382X appear to be founder
mutations. Although the common origin of P28T has been confirmed by haplotype analysis
in six Gypsy families from Bulgaria (Kalaydjieva et al., 1999), it is unclear whether the same
mutation accounts for all affected individuals among the European Gypsies. No haplotype
analysis has been conducted among the Costa Rican/Europeans with Q382X, therefore a
founder effect can only be assumed.
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2.6

Summary

Clearly, the lack of conclusive data about both the functional and structural
characteristics of the CALK! gene, as well as the influence of age, tissue specificity and
allelic variation upon the encoded enzyme product, allows only a limited insight to the
complete process of galactose metabolism. One way towards understanding this process is

futther analysis of the CALK/ gene. Any mutations found during such investigations will
help the progression towards a complete characterization of the galactokinase gene and

galactose metabolism. Furthermore, the lack of conclusive information regarding the
frequency and distribution of common mutations in the GALKJ gene needs to be
addressed to allow further research into genotype/phenotype correlations. Not only will

this aid in the development of newborn screening strategies in high risk groups and

prevention of infantile blindness, but will also allow the link between partial deficiency and
presenile cataract development to be fully investigated.
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CHAPTER 3 IDENTIFICATION OF GALK/ MUTATIONS IN PATIENTS
WITH GAIACTOKINASE DEFICIENCY
3.1 SUBJECTS
Patients included 9 individuals with galactokinase deficiency. Most had been detected
as hypergalactosemic by newborn screening (fable 3.1). The exception was a Gypsy child
from Bulgaria, who had undergone surgery for infantile cataracts. The patients are on

galactoseMrestricted diet and are symptom-free. Galactokinase deficiency (< 5% of the
lower limit of the normal range} was confirmed by enzyme activity measurements in red
blood cells (RBC). All patients have normal galactose-1-phosphate uridyl transferase and
UDP-epimerase RBC activity.
Table3.1
Biochemical Findin~s of Study Sample
Patient

!•
2'

Hypergalactosemia

+
+
+
+
+
+
+
+
+

)•

4'
5•
6d
7d
Sd

9•

Galactosuria Galactokinase

+
+
+
+
+
+
+
+
+

Deficient
Deficient
Deficient
Deficient
Deficient
Deficient
Deficient
Deficient
Deficient

RBCAttivi
G·l·P
uridyl transferase

ep1merase

Nonnal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal

Normal
Nonnal
Normal
Nonnal
Nonna1
Nonnal
Normal
Normal
Normal

UDP·

Origin
European/America
Twlillh
European/America
Spanish Gypsy
Spanish Gypsy
Hungarian Gypsy
Hungarian Gypsy
Hungarian Gypsy
Bulgruian Gypsy

• Dept of Pediatrics, Harvard University Medical School, Boston, USA
b Univenity Ollldren's Hospital, Zurich, Switzerland
c Institut Bioquimica dini.ca, Barcelona, Spain
d Dept. of Pediatrics, Medical School, Szeged, Hungary
e Bulgaria

The DNA samples of these patients have been provided for analysis by the Genetic
Service, Children's Hospital and Department of Pediatrics, Harvard Medical School,

Boston, USA, the University Children's Hospital, Zurich, Switzerland, the Institut
Bioquimica Clinica, Barcelona, Spain and the Depanment of Pediatrics, Medical School,
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')zeged, Hungary. DNA from three individuals without galactokinase deficiency were used
o1s controls and were sequenced in parallel with patient DNA. These samples were chosen
from a DNA bank maintained within the Centre for Hwnan Genetics at Edith Cowan
University.
Consent for DNA analysis was obtained from the parents of all participants in the
study. The investigation complies with the guidelines of the Edith Cowan University Ethics
Committee.
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3.2METHODS
3.2.1 Experimental Design
The strategy used in the current investigation included:
a} Detection of mutations: -

by sequence analysis of the entire CALK! coding region,
flanking intronic sequences and both the 5' and 3' UTR.

by direct testing of the P28T mutation in individuals of
Gypsy ethnicity.
b) Independent confirmation of identified variants using other methods of mutation
detection:

confirmatory analysis of the original DNA sample using an
independent PCR amplification and a different method.
screening a panel of 50 Caucasian controls (100 chromosomes).

c) Computer analysis:

comparisons of sequences.

analysis of the nature of the sequence variants.
predicted effects on protein structure/function.

3.2.2 DNA Q~tantification
The concentration of the provided DNA samples was detennined using a Beckman

ou• 640 UV spectrophotometer. This is achieved by reading the absorbance of a DNA
sample in d.H20 c:t a wavelength of 260nrn. Concentration of each sample can be calculated
using the fact that one optical density unit at this wavelength equates to

SO~g/ml

of DNA

(Sambrook, Fritsch, & Maniatis, 1989). The ratio between the readings at 260nm (DNA)
and 280run (phenolic rings) provides an estimate of the purity of the nucleic acid. Knowing

the starting concentration of each of the DNA samples allows the accurate dilution to a
suitable working solution. For the purposes of this study, a concentration of 20ng/11l of

DNA was employed.
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3.2.3 PCR Amplificatio"
Amplification of GALKJ was perfonned using the polymerase chain reaction (PCR).
This procedure has revolutionized molecular investigations of the genome, allowing great
specificity and ease in obtaining a large number of copies of template DNA from even the
smallest concentration of starting material. A standard PCR reaction involves the addition

of a heat-stable DNA polymerase, dNTPs, sequence specific primers, buffer, dH 20 and
MgCl2 , to a sample of DNA Successive temperature cycling causes denaturing of DNA to

single-stranded templates, then a period of cooling to allow the annealing of
oligonucleotide primers, followed

by another temperature change that allows activation of

the polymerase. The activated polymerase catalyses synthesis of new DNA strands, utilizing
the provided d.NTPs in the reaction. With continued cycling, an exponential increase in
DNA templates is achieved. A number of parameters may influence the yield of the desired

target product and can be adjusted accordingly to obtain optimal amplification. Some of
these include concentration, quality and the sequence of starting DNA, reagents, cycling
times, temperature and the addition of solvents such as DMSO for fragments with high
denaturation temperatures.

Primers previously used for PCR amplification of GALKI were utili:red for obtaining
the sequence of the coding regions of the gene and at least 100 bp of flanking intronic
sequences (Table 3.2). Primers for the entire S'UIR were designed from the published
GALKI sequence (Genbank Accession ' L76927). Due to suspected errors in the
published 3'UTR sequence, primers for this region were selected from the Homo sapiens

chromo.<ome 17 clone RP!l-4741111 (Genbank Accession' AC019214). Optimal cycling
conditions and parameters were determined for each fragment using a series of MgCl2

titrations (1mM, 1.3mM, 2mM & 2.5mM) and DMSO concentrations (1-5%) and run upon
a PTC-200 gradient thennal cycler (MJ Research Inc.). PCR amplification of DNA
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Table 3.2
PCR Primer _Sequences and Conditions for GALJ(l
GAl.K1
Rc ·on
5'UTR (F)
5UI'R(R)
5UI'R (F)
5UI'R (R)
I (F)
1 (R)
2(F)
2 (R)
3(F)
3 (R)
4(F)
4 (R)
5(F)
5 (R)
6(F)
6 (R)
7(F)
7 (R)
8(F)
8 (R)
3'UIR (F)
3'UIR(R)

Primer sequencea
5'-CI'GATGA=CTCACAGCfGC-3'
5'-CGAAGTcx:AGAGGGAAGGAC3'
5'-CI'ATTCTCACTCTAGTGAGTGC-3'
5'-CGTCATGGCfGCTTTGAGACAG-3'
5'-=GAGCAT=GCCGAC3'
5'-GACAGGCfGTT=::cACGT-3'
5'-ACTGTGGAGGCATCAGAAC:C3'
5'-CACAGAGCcx:ATTCATTTGTCTGA-3'
5'-CCTAGAAACAGTTGCfAGGC-3'
5'-GTGGTox:AGCTTCTACTAT-3'
5'-AGTGTCATTGAAGCCACTGC3'
5'-CAAGCACACGCTTGGCCTCGT-3'
5'-AGCAGCf=GGGTGGAGTGT-3'
5'-CI'CAGTGTGGCCTTGA=-3'
5'-ATCACCGCCTGCfGGT=C3'
5'-CCCAGGCcx:Acc=TCAATA-3'
5'-CI'CATGGTGGAGAGCCACCG-3'
5'-CI'CAAGCAGCCGATGGAGCC3'
5'-ACGCCATGCGGCACATcx:AG-3'
5'-CI'CTGT=GGTGCCATCTT-3'
5'-GCTGTGCTTGTGAGGCAC:C3'
5'-CTTCCAAACTTGACCGCA=·3'

• Adapted from Kalaydjieva et al (1959)

b Nucleotide nwnbering based upon Genbank accession#L76927

~
~

Nucleotide

PCR

positionb

Conditions

1-21
224-243
188-209
473-499
419-438
800-818
1436-1455

Additives

Notes

SS"C for 35 cycles 1.5 mMMgC!,
63"C for 35 cycles 1.5 MgCI,

63"C for 35 cycles 4% DMSO, 1.25mM MgCI,

Jv1anual hotstan

TD 63'C->56"C

4% DMSO, 1.5mM MgCI,,

TD 63"C-+55"C

4% DMSO, l.SmM MgCb

1D 63°C-)-57°C

1.5 mMMgCI,

2647-2667
2971-2990

TD 63"C-+55"C

4% DMSO, 1.5mM MgC!,,

11anwl hotst.m

6945-6964
7217-7238
7146-7165
7530-7549

1D 63°C-).55"C

4% DMSO, I.OmM MgC!,,

Manual hotstan

65"C for 30 cycles 4% m ISO, I.OmM MgC!,

M.lilual hotst.m

7394-7413

1D 63"C-+55"C

7624-7644
7555-7573
8059-8081

63"C for 30 cycles 4% DMSO, 1.5mM MgCI,

1781-1805
2071-2090

2354-2373
2408-2427
2686-2706

4% DMSO, 1.5ffi1.1 Mgd~

according to the optimized conJitions was carried out in 501-11 reactions. The conditions arc

detailed in

To~ble

3.2. Both the 96 well

PTC-100~

Programmable Thennal Cycler {MJ

Research Inc.) .md the Gcneamp PCR systc·m 2400 (Applied Biosystems) were used for
PCR cycling.
To check the successful amplification of each genomic target, all PC:R products were
size-sepo1rated by gel electrophoresis. 2.5% agarose milligels were prepared by adding 2.5

grams of DNA grade agarose powder to lOOmis of IxTAE buffer. The solution was heated
in a microwave oven until agarose had dissolved, and placed in a dry incubator to cool to
60 degrees C. Prior to pouring, 3.51-11 of ethidium bromide was added to each agarose

solution to allow lN visualization of PCR products. The agarose solution was poured into
Perspex casting trays to a depth of approximately Smm, well combs were insened and the
gel allowed to set at room temperature under a fumehood for 30 minutes before use.
Combs were then removed and the gel was placed into an electrophoresis tank (Biorad

Mini-Sub • Cell GT), !xTAE buffer was added to cover the gel to a depth of approximately
2-3mm.

5~1

of each PCR product were mixed with

1~1

of loading buffer (0.25% bromo

blue, 0.25% xylene cyanole, 15% ficoll) and loaded into single lanes of the gel. A

1~1

aliquot

of pUC!9/Hpa II (PE Biosystems) DNA molecular marker was loaded into the left-hand
side of each gel co give an indication as to the size of each PCR product. The

pUC!9/Hpall ladder gives a series of bands of known nucleotide length ranging from 26
to SO! bps. This allows a visual size estimation of the PCR product to be obtained and
compared with the expected fragment length. Each gel underwent electrophoresis at 80V
for approximately 30 minutes and was then removed from thr electrophoresis tank and
visualized on a Hoefer Mighty BrightTll UV Illuminator. Images were recorded using a

Kodak" DC120 digital camera and Kodak" Digital Science~ software.
After confirming sufficient amplification, PCR products

were cleaned of

unincorporated dNTPs, primer dimers and amplification primers, using the QIAquick

34

purification kit (QIAGEN, Austr.tlia). This entailed the addition of 5 volumes of PB buffer
to e.tch PCR product. Each sample was inverted to mix, then pipcttcd into a separate

QIAquick

spir1

colwnn. DNA

WolS

bound to the QIAquick membrane by centrifugation at

15 000 rpm for 1 minute in an Eppcndorf 54 17c centrifuge. The flow~through was

discarded before the addition of 7501-11 of PE wash buffer and further centrifugation at 15
000 rpm for l minute. The flow-through from this step was discarded and an additional
spin under the same conditions was performed to remove any residual PE buffer. Columns

were then placed into sterile, labeled l.Sml Eppendorf tubes and the bound PCR product
eluted with the addition of 30~1 of dH,O and a final spin at IS 000 rpm for I minute.
Eluted DNA was then stored at -20 degrees C until further analysis.

3.2.4 Big Dye Terminator Cycle Sequencing
Clean PCR products were sequenced using the ABI PrismTll Big Dye Tenninator

Cycle Sequencing Ready Reaction Kit. This procedure invoives the incorporation of a
fluorescent-labeled

dideoxynucleotide

at

the

3'

end

of

DNA

strands.

The

dideoxynucleotide prevents further elongation of the template DNA and as its addition is
mediated by competition with its corresponding unlabelled dNTP added to the same

reaction, a series of fragments of different sizes are produced.
Each reaction was prepared on ice and consisted of 1-2~1 of target DNA (20ng/~l),
4~1 of BigDye Terminator, 1~1 of forward or reverse primer (20ng/~l) (Table 3.2) and

dH,O to a final volume of 10~1. Reactions were then placed in a 96 well PTC-100~
Programmable Thermal Cycler (MJ Research Inc.) under the following cycling parameters:

rapid thermal ramp to 96 degrees C, held at this temperature for 10 seconds, a rapid
thermal ramp down to 50 degrees C helci for 5 seconds. This was followed by rapid

ramping to 60 degrees C and held for 4 minutes. This cycling was repeated 24 mere times.
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3.2.5 Ethanol/Sodi~tm Precipitation
Sequencing reactions were cleaned using a precipitation reaction designed to remove
excess nucleotides and primers that would otherwise interfere with the accuracy of the

sequence signal. This entailed the addition of 1~1 of 3M sodium acetate (pH 4.6) and 25~1
of 95% ethanol to each sequencing reaction. Tubes were inverted to mix, then left at room
temperature for 15 minutes to allow the precipitation of extension products before
centrifugation at 3000 x g for 30 minutes in a Hermie Z823 centrifuge. Open tubes were

then inverted on a tissue folded to fit the size of the carry tray and then spun at 700 x g for
1 minute to remove any residual ethanol. 75~1 of 70% EtOH was then added to each tube
and again tubes were inverted to mix before centrifugation at maximum speed for 10

minutes. Open tubes were then placed upside down on a clean folded tissue and spun at
700 x g for an additional minute before being left to air dl)' for approximately 10 minutes

to ensure complete evaporation of residual ethanol.

3.2.6 Sequencing Gel Preparation
Sequencing gels were prepared by adding 5 ml of filtered 10XTBE to 18g of urea in a
SOrnL glass graduated cylinder. 4.75mL of LongRanger Gel solution was added to this mix
before the addition of dH,O to a final volume of 45rnL. The top of the cylinder was

covered with paraftlm and inverted to dissolve the remaining urea. The final volume was
brought to SOml with dH,O. The solution was filtered using 0.2~m filter paper before
degassing for 10 minutes in a vacuum. Prior to pouring the gel, 250~1 of 10% APS
(anunonium persulphate) and 35~1 of TEMED (N',N,N',N'-tetra-methylethylenediarnine)
were added. The solution was poured using a 50 ml syringe, the loading inserted and the gel
assembly clamped. The gel was left to set for approximately 2 hours before fitting to an
ABI Prism~ 377 DNA Analyzer.

36

3.2.7 Electrophoretic Conditions
Priorto loading, 4~1 of a 5:1 EDTA (SOmM) + Blue dextran (SOmg/ml)i Formamide
loading solution were added to each precipitated reaction pellet. The reactions were
denatured for 3 minutes at 94 degrees C. Products were then snap-chilled on ice to ensure

they remained in a single-stranded conformation. l1-1l of each sequencing reaction were
pipetted into alternate single lanes of the gel, pre-warmed to 51 degrees C. Samples were

run for 2 minutes before sequencer was paused and the remaining samples loaded in
adjacent empty lanes. The electrophoresis was run for 11 hours at 2400V. Sequencing data

were downloaded to an iMAC-Macintosh computer and analyzed using the Sequence
Navigator~

(PE Biosytems) software.

3.2.8 Web-Based Databases Utilized in the GALKl Analysis
A number of web-based genomic and protein databases and tools have been
developed to cope with the increasing amount of sequence data being deposited in the
public domain. A nwnber of these were utilized in the rurrent investigation.

3.2.8.1 Nuclrotide andprot£inSffJUD1CES
The nucleotide and the amino-acid sequences of the Homo sapiens GALKJ gene

and galactokinase protein were obtained from the National Centre for Biological
Information (NCBQ available at [http:! /www.ncbi.nlm.nih.gov]. Genbank accession
numbers L76927, AF084935 and U26401 were utilized for nucleotide comparisons.
Protein sequence and codon numbering were derived from Genbank Accession ~

PS00106.

3.2.8.2 Residuelxmdctgy
The BLAST alignment program, available at [http:/ /www.ncbi.nlm.nih.gov/BLAST/],
was utilized to establish whether mutations ocrurred at evolutionary conserved
residues. It is assumed that conserved residues are under positive selection and are
thus maintained across species due to their functional significance for the encoded
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protein. The BLASTP alignment compares characterized protein sequences deposited
in the public databases to a query sequence. In this study the human galactokinase
protein sequence was compared with the galactokinase protein sequences of
approximately 20 organisms.

3. 2. 8.3 Restriaim endm:clmse selroWn
The WebCuner program available at [hnp://www.firstmarket.com/cuner/cut2.html]

was used to determine whether the detected nucleotide changes produced or
abolished restriction endonuclease recognition sites. The WebCutter software utilizes
a database called REBASE available at [http://www.rebase.neb.com]. The database

is a compilation of characterized restriction endonucleases and associated recognition
sites that is updated on a regular basis (Roberts & Macelis, 2000).

3.2.8. 4 Motifdete:Iim <1T7d ali1!J1117mt
web-based

The

motif

alignment

tool

SPRINT,

available

at

[http://www.bioinf.man.ac.uk/dbbrowser/sprint/], was used to calculate and
identify significant regions of homology between the human galactokinase protein

and the sequences of galactokinase proteins from other organisms. The purpose of
the motif alignments is to compare known or similar motifs in other proteins
deposited in the public databases and obtain an indication as to the function of a
protein or the family to which a protein sequence belongs.

3.2.8. 5 Seandttry St:rudural Prrrlicticn
Computer modeling of the predicted structure of the mutant protein was done with
the

PHDsec

algorithm

(Rost

&

Sander,

1994)

available

at

[http://dodo.cpmc.columbia.edu/ predictprotein/submit_def.html]. This algorithm
calculates the conformational probability that a specific residue will result in the
formation of a helix, loop or extended beta-sheet in the second:uy folding of the

protem.
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3.2.9 Mutation Detection Techniques
Nucleotide changes were also independently detected on a second PCR product
derived from genomic DNA of each patient by using various mutation identification
methods, including restriction endonuclease assays, single strand conformational

polymorphism (SSCP) and heteroduplex analysis (HDA). The principles and methods for

each of these techniques are described below.

3.2. 9.1 RestrictWn Endmudease Assays
Nucleotide changes were detected using restriction endonucleases. Isolated from

prokaryotic organisms, these enzymes cut DNA at specific recognition sites. Their
natural function is to remove foreign DNA sequences from the host genome. They
also provide a useful tool for mutation detection if the nucleotide change in question
abolishes or creates a recognition site differing from the wild-type sequence. Four
restriction enzymes were utilized in the current analysis: N1aiii (New England
Biolabs cat' R012SS), AlwNI (New England Biolabs cat' ROS14S), Bbvl (New
England Biolabs cat' R0173S) and Ava! (New England Biolabs cat' R0152S). For
the Bbvl assay, 10~1 of product {"100ng/~l) was digested with 1~1 of enzyme (2
units/~!), 2~1 of 1x NE buffer and 7~1 of dH,O in a final reaction volume of 20~1.

The protocol for the Ava!, Nlalll and AlwNI assays differed by the addition of 2~1
of 1 x BSA (bovine serum albumen). All digests were incubated at 37 degrees C for
2hours. Products from the Ava!, Bbvl and Nlaiii digest were then run upon a 4%
agarose/EtBr gel at 60V for 1 hour and visualized on a Hoefer Mighty Brightm UV
Illuminator and the image was recorded using a Kodak• DC120 digital camera and

Kodak• Digital Sciencenl software. The AlwNI digest products were run on 12%
PAG gels in 1 X TBE buffer for 1 hour at 200V. Gels were then silver stained
according to the protocol in Section 3.2.9.2
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3.2.9.2 SSCP and HDA M11tatim Deta:tim
Single~strand

conformation polymorphism (SSCP) is a mutar.ion detection technique

which relies on the fact that single base changes and deletions may cause changes to

the primary folding of each DNA strand resulting in aberrant electrophoretic

patterns {Orita, Suzuki, Sekiya, & Hayashi, 1989).
Heteroduplcx {HD) analysis involves the detection of similar shifts in mobility of
mismatched duplexes of DNA strands, caused

by single base substitutions and

particularly insertions and deletions (White, Carvalho, O'brien, & Dean, 1992)
SSCP analysis involves denaturation of a double-stranded PCR product with
formamide and heat and are snap·chilled on ice before electrophoresis on a

nondenaturing polyacrylamide gel. For HD analysis, PCR products are denatured
without formamide and are allowed to cool slowly so as to form both matched

(homoduplex)

and

mismatched

{heteroduplex)

DNA

duplexes

before

electrophoresis.
For both SSCP and HD analysis, a 140 bp product of exon 5 was amplified using
forward primer 5'-CCAGGTCCITGGAGACCAGC-3' and reverse primer 5'CAi\.GGAAAGCCfC:CGGGAGG-3'. Cycling conditions for this fragment included
initial denaturation at 94 degrees C for 5 minutes, followed by 16 cycles using '
touch-down regime of denaturing at 94 degrees C for 30 sec, annealing from 63
degrees C to 55 degrees C {0.5 degrees C increments) for 30 sec and extension at 72
degrees C for 30 sec. This was followed by 20 cycles of 94 degrees C for 30 sec, 55
degrees C for 30 sec and 72 degrees C for 30 sec before final extension at 72 degrees

C for 7 minutes.
PCR products for SSCP analysis were prepared by adding 2~1 of formamide
loading buffer {98% formamide, 0.025% xylene cyanol & 0.025% bromophenol blue)
and 2~1 of dH,O to 2~1 of each PCR reaction. Samples were denatured for 3 minutes
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at 94 degrec::s C before being snap·chilled on ice prior to loading. Heteroduplcxes
were gencrJ.tcd by independently amplifying the same exonic fragment and then
subjecting 3~1 of PCR product to post-amplification denaturation for 3 minutes at 94
degrees C. Samples were then allowed to cool to room temperature over a two hour
duration. Prior to loading, 3~1 of ficollloading buffer was added to each tube.
Products were run on 12% PAG (29:1 bis-acrylamidc) non·denaturing gels in a
ice-cooled buffer consisting of 1 x TBE and 5% glycerol. Electrophoresis was canied
out in a Mini-Protean • Cell II tank (Biorad) at 200V for 2hrs.
Gels were stained using a silver staining technique, which offers a higher degree
of sensitivity than ethidium bromide in detecting and visualising DNA on thin gels.
After electrophoresis, gels were soaked in 10% ethanol solution and gently agitated
for 3 minutes. This solution was drained, and sufficient 1% nitric acid was added to
cover the gel(s). Again, gels were left to soak for 3 minutes before the solution was
drained and three washes with dH,O were performed. Gels were then soaked under
gentle agitation in 0.1% silver nitrate solution for 10 minutes in a light-protected tray.
The solution was discarded and gels were washed three times in dH20. A solution
made up of 25g of sodium carbonate dissolved in 250m! of dH,O plus 300~1 of
formaldehyde was used to develop the DNA bands. Gels were soaked for
approximately 1 minute until the solution changed colour. The developing solution
was then drained and a fresh measure was added. The gels were left to soak under
gentle agitation until the bands were seen. The remaining solution was discarded and
the developed gels were rinsed three times in dH20 before fixation in a 10% acetic
acid solution for 10 minutes. A final rinse with dH,O was followed by a 10 minute
soak in 1% glycerol to prevent cracking of the gel during the dtying process. Gels
were placed between two drying film sheets and clamped within a Promega gel
drying rack and left in the fumehood to dry overnight. Dried gels were photographed
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on a light box using a Kodak' DC!20 digital camera and Kodak' Digital Science~
software.
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I
3.3 RESULTS
Analysis of the CALK! gene m nine patients detected one previously identified
disease-causing mutation and 4 novel mutations that are likely to cause the galactokinase

deficiency phenotype (Table 3.3).
Table 3.3
GALKJ Mutations in Patients with Galactolcinase Deficieng::.
Patient

RBCGK
activity

I

Deficient

Nucleotide
changea
1569 C-tT
753SG~C

2

Deficient

3

Deficient
Deficient
Deficient
Deficient
Deficient
Deficient

4

5
6
7
8
9

Deficient

7093C~T

2833ddC
563C->A
563C->A
563C-)A
563C--'~>A

563C->A
563C--:~-A

563C->A

Amino add change

R68C
A384P
T288M
Frameshift after Y236
P28T
P28T
P28T
P28T
P28T
P28T
P28T

Exo

2
8
6
5
I
I
I
I
I
I
I

Genotype

Ethnic

Orip:in
Heterozygous European/ American
Heterozn;ous

Heterozygous European/American
Heterozygous

Homozygous Turl<ish
Homozygous Sp""'h Gyp')'
Homozygous Spanish Gypsy
Homozygous Hungarian Gypsy
Homozygous Hungarian Gyp5)'
Homozygous Hungarian Gypsy
Homozygous Bulgarian Gypsy

• Nucleotide numbering according Genbank Accession' 176927.

33.1 Patient 1

Patient 1 is a compound heterozygote for two nucleotide changes that result in the
novel missense mutations, R68C and A384P.
R68C
Sequence analysis revealed a 1569C--> T transition in exon 2 (Figure 3.1). The

1569C-+T transition is predicted to result in the replacement of arginine by cysteine at
codon 68 (Figure 3.2). The arginine residue at this position is strictly conserved in the

galactokinase protein of over twenty different species checked, including the mouse. The
mutation is a drastic change from a charged to an uncharged amino acid residue with a
sulfhydryl side-chain (Figure 3.3), however the computer predictions did not suggest

significant alterations in tl-te secondary structure of the mutant protein (Figure 3.4).
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CAGN/ CIG
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Figure 3.5 AlwNI restriction digest detecting 1569C~T transition in exon 2 on silverstained 12% PAG. Lane 1: Undigested exon 2 patient 1. Lane 2: pUC1 9/Hpaii Ladder.
Lane 3,4, 6-12: Unaffected. Lane 5: Patient 1 digest.
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The highly conserved nature of the amino acid residue, as well as the drastic nature of the
substitution coupled with the fact that the mutation did not occur among control
chromosomes, suggest that it it is likely that R68C is a clisease-causing mutation.

A384P
The second mutation carried by patient 1 is a
8 (Figure 3.6). The

7538G~C

7538G ~ C

transversion found in exon

base change leads to the substitution of proline for alanine

at position 384 of the galactokinase protein (Figure 3.7). Both alanine and proline are nonpolar amino acids (Figure 3.8). Alanine at this position is not highly conserved, it is present
onJy in the two mammalian gaJactolcinases characterized so far, human and mouse, and
sequence similarity is found in the proteins of seven additional species.
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Figure 3.6

7538G~C

transversion in GALK1 exon 8 causing A384P.
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Figure 3.7 Residue c~ange at codon 384 caused by the 7538G~C transversion. Wildtype
alanine is replaced with proline.
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Figure 3.8 A384P- molecular comparisons between the alanine and proline residues
The substitution of proline for alanine is likely to induce significant topological

changes, as predicted by the secondaty structural analysis. The helix formed between the
F378 and A384 residues in the wild-type protein is abolished by the mutation, which also
leads to an extension of the beta sheet and causes loop formation by adjacent residues

(Figute 3.9). A384P is located 8 amino acid residues upstream of the carboxyl tenninus of
the protein and is the second reported mutation in exon 8, after Q382X (Kolosha et al.,
2000), suggesting that this part of the protein is essential for galactokinase function.
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Figure 3.9 Secondary-structure prediction for the wild-type exon eight galactokinase
sequence and the A384P missense mutation using the PHDsec algorithm. P384 in
boldtype face. E - extended sheet (beta sheet); H- helix; L - loop. The prediction is
meaningful for all residues with an expected average correlation > .69.
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The 7538G---7C transversion (A384P) abo lishes a Bbvl endonuclease restriction site
marked by the sequence 5' GCAGCNx 3' and 3' CGTCGN 12 5'. T o confirm that the
transversion does not occur in the wild-type population, a Bbv I restriction assay was
performed on the PCR product encompassing the entire exon 8 sequence from both th e
proband and SO unaffected controls (Figure 3.10). The 7538G---7C transversion was not
detected among the control samples assayed .

Bbvl recognition sequence

5' GCAGCN~ 3'and 3' CGTCgN, 2 5'

Restriction map
Bb\"1

Wildtypc _ _ _ _..,.,_ _ _ _ _ _ _ _......,111!"'"_ _ _ _ 250 bp

Bb\"1

7538G-tC:

250bp

56

Expected banding pattern
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7538G-tC:
heterozygote
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Figure 3.10 Bbv I Restriction Digest of Exon 8 PCR Product. Lane 1: pUC19/ Hpa II
Ladder. Lane 2: Undigested exon 8 of patient 1. Lane 3: patient 1 digest. Lanes 4,5,6:
Unaffected controls.
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It is likely that A384P is a disease-causing mutation based upon the fact that it
induces topological changes in the secondary structure of the protein, resulting from the
change from an aliphatic (alanine) residue to a cyclic (proline) residue. This is supported by
failure to detect it among 100 control chromosomes.

3.3.2 Patient 2
Patient 2 is heterozygous for a nucleotide transistion in exon 6 and a single base
deletion occurring in exon 5. The patient was also heterozygous for nucleotide transitions
in the S'UTR (303A---7G) and intron 2 (2148C---7T).

T288M
Sequence analysis detected a C---7T transi tion at nucleotide 7093 (Figure 3.11). The
7093C---7T transition causes the substitution of methionine for threonine at codon 288
(Figure 3.12). Although the mutation results in the replacement of a polar amino acid
residue by a nonpolar with a sulfur-containing side-chain (Figure 3.13), the secondary
structural predictions are inconclusive (Figure 3.14).
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Figure 3.11 7093 C---7T transition in GALK1 exon 6 causing T288M .
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T288M is th~ first mutation identified in cxon 6 of GALKJ and occurs in a region

identified

by

the

web-based

motif

alignment

tool,

SPR!Nf

(available

http:/ /www.bioinf.rnan.ac.uk/dbbrowser/sprint/) as encoding a conserved galactokinasc
fin~erprint motif sequence. As shown by the sequence alignment of this ga1actokinasc motif

(Figure 3.15), the threonine residue at position 288 is conserved in nine out of twenty
galactokinases. The residue at this position in all but one of the remaining galactokinases is
valine, which does not differ drastically in terms of side~chain structure from threonine.
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Figure 3.15 Galactokinase fingerprint motif four. Bold highlight showing amino acid
variation analogous to residue 288 of the human galactokinase protein at which the T288M
substirution is found. Methionine at this residue is not shared by any of the galactokinases

that share the fourth galactokinase fingerprint motif. Motif alignment by SPRINT
(available http://www.bioinf.man.ac.uk/dbbrowser/sprint/)
The 7093C~T change creates a Nla III endonuclease restriction site by forming

the recognition sequence CATG/ (Figure 3.16). Exon 6 of the affected proband was
amplified by PCR using previously described primers and conditions (Table 3.2). The
mutation was tested in the panel of control individuals using the restriction assay. It was
not found among 100 normal chromosomes.
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Nlalll recognition sequence
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---- - - - - - - - - --- Figure 3.16 Nla III Restriction Digest of 7093 C~T (f288M) in exon 6 PCR Product.
Lane 1: pUC19/Hpa II Ladder. Lane 2. Undigested exon 6 of proband. Lanes 3-8 & 10:
Unaffected controls. Lane 9: Patient 2 digest.

It is likely T288M is a disease-causing mutation based on the drastic nature of the
substitution, the observation that it occurs within a fingerprint motif sequence at a residue
that shows a moderate degree of conservation and the failure to detect it among 100
control chromosomes.
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2833delC
A si ngle base-pair deletion, 2833dciC (Figure 3.17), was found in exon 5, where one
missense and another truncating mutation have been reported previously (Asada et al.,
1999; Kolosha et al., 2000). The 2833deiC mutation is preclicted to result in a frameshift
(Figure 3.1 8) and a premature termination signal at codon 263, leading to a protein that is
130 amino acids shorter than the wild-type enzyme (Figure 3.19). The presence of the
deletion was independently confirmed by single strand conformational polymorphism
(SSCP) and heteroduplex (HDA) analysis. The SSCP analysis proved to be a more
definitive detection technique for the 2833delC deletion as evidenced by the aberrant
banding patterns differing from the wild-type controls seen in Figure 3.20.
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Figure 3.17 2833delC in exon 5 resulting in a shift of the reacling frame at codon 237
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Figure 3.18 Frameshift at codon 237 caused by the 2833delC deletion. Wildtype proline is
replaced by leucine arid novel protein sequence.
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SLETSLVPLSDPKLAVLilNSNVIU JSL\SSEYPVRRRQCEEV AR.ALGKESLREVQLEELE
SLETSLVPLSDPKL-\ VLITNSNVIU-ISLASSEYLCGGAN.VKKWPGRWARKASGRYNWKS*

Figure 3.19 Protein sequence of CALK! cxon 5 wild-type (upper sequence) and novel
protein sequence Qower sequence) and premature stop sig nal resulting from the frames hi ft
caused by 2833dc!C.

HD:\

Lane

1

2

3

SSCP

4

5

6

7

8

9

10

Figure 3.20 Detection of the 2833delC in GALK1 exon 5 by heteroduplex analysis HDA
and single strand conformatio nal polymorphism SSCP. Products were run on 12% PAG at
200V fo r - 2hrs. Lane 1: pUC19/ Hpai marker. Lanes 2,3 & 5: Unaffected controls. Lane 4:
Patient 2 HDA Lane 6: pUC19/ Hpai marker. Lanes 7, 9 & 10: Unaffected controls. Lane
8: Patient 2 SSCP.
Schematic representation of aberrant banding pattern as detected by SSCP

Wild type

2833de1C
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Other Nucleotide changes
Pottiem 2 is heterozygous for a 2148C--).T transition in intron 2. This change is

located 34 bp upstreoun of the 5' end of cxon 3 and 3 bp upstream of a putative eukaryotic
consensus branch point sequence, YNRA Y (Rautmann & Breathnach, 1985, Chiara ct al.,

1996). Patient two is also heterozygous for a 303A_,G transition in the SUTR This base

change occurs within the 250 bp putative cukaryotic polymerase II promoter region
(Bergsma et al., 1996). As it seems likely that both disease-causing mutations (T288M and
2833delC) have been identified in the coding sequence of the GALKI gene in this
individual, it is probable that both 303A->G and 2148C->T, which occur in non-coding
regions, are not involved in the deficiency phenotype.

3.3.3 Patients homozygous for the P28T mutation
3.3.3.1 Patimt 1hrre

This individual was characterized by sequence analysis and found to be
homozygous for a 563C---1>A transversion in exon 1, resulting in the previously

identified missense mutation P28T.
P28T
Sequencing revealed a 563C---+ A transversion on both the forward and reverse
strands of DNA. The mother of this patient is heterozygous for this nucleotide
change (Figure 3.21). This nucleotide transversion results in the substitution of
proline for threonine at codon 28 and has been previously shown to induce
topological changes in the secondary structure of the protein (Kalaydjieva et al.,

1999). The P28T mutation occurs in close proximity to the galactokinase signature
sequence m exon 1 signaling the importance of this region to normal enzyme
function.
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Figure 3.22 Ava I restriction endonuclease digest of 563C-7A transversion. Lane 1:
pUC19/ Hpall marker. Lane 2: Undigested exon product. Lanes 3 & 4: Unaffected
controls. Lane 5: Mother of patient 3. Lane 6: Patient 3. Lanes 7 & 8: heterozygous
controls. Lane 9: hompzygous control. Lane 10: negative control.
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3.3.3.2

Patimts ofGypsy etlmic hackg1uwl

All six patients, belonging to Gypsy groups geographically dispersed throughout

Europe (fable 3.3), were homozygous for the 563C->A transversion (P28T) as
detected by the A val restriction assay. The P28T substitution) previously described as
a founder mutation, occurs in high frequency in the Vlax Roma Gypsy population in

Bulgaria (Kalaydjieva et al., 1999). The fact that this mutation is shared amongst
affected individuals across Europe suggests that P28T may have a more widespread

distribution 1:han first thought.

3.3.4

Non~disease

causing nucleotide variations

In addition to the nucleotide changes that were detected in the sample of patients, a

number of differences from the existing published GALKJ sequence were also identified in

both affected and unaffectod individuals run in parallel. These are detailed in Table 3.4.

Table 3.4
Nucleotide Differences Between Published GALKI Sequences.
Nucleotide II
Genbank Accession
NL76927
415
418
694

2149
2151
2172

Region
5UTR
5UTR

intron 1
intron 2
intron 2
cxon3

Nucleotide and Source
Bergsma ct al. (1996)• Asada ct al. (1999)L
(n-7)

C

C
C

T

T
T

This study
(n-9)

T
T

T

C

G

G

A
C

C
ddC

ddC

c

• Gcnbank accession * U6927
b Genbank accession ' AF084935

The nucleotide changes agree with those reported in a previous study of both affected

and unaffected Caucasian and Japane'e individuals (Asada et al., 1999). l11is suggests that the
changes are probably errors in the original sequence (Bergsma et

al., 1996) rather than true

sequence vanants.
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3.4 DISCUSSION
The sequence analysis of the enure CALK! coding reg10n, flanking imronic
sequence and both tht: 5' and 3' UTR in three patients with galactokinase deficienc-y
revealed 3 novel missense amino acid substitutions {R68C, A384P, T288M) and a single
base deletion (2833deiC) which are likely to be disease-causing mutations. In addition one
previously characterized missense mutation {P28T) was also detected.

3.4.1 Nature of the newly identified mutations
The R68C substitution in exon 2 occurs at a highly conserved residue that is
preserved in the galactok.inase protein sequence of a wide number of organisms including
the mouse, yeast and bacteria. This high degree of evolutionary conservation, coupled with
the nature of the amino acid substitution, suggests that this mutation is responsible for an
interruption to normal galacrok.inase activity. As the substitution does not occur in a
recognized motif sequence, the role that this region of the gene has in the normal activity
of the enzyme is unclear. R68C is the fourth mutation described in exon 2, the remaining
three being truncating mutations (Stambolian et al., 1995; Kolosha et al., 2000).

The A384P change in exon 8 occurs at a residue that is conserved in the murine
protein sequence and shares a homologous residue among bacteria and yeast. This
substitution also occurs 2 residues downstream of a previously identified Q382X mutation
implicated in causing a reduction in galactokinase activity (Kolosha et al., 2000). The dose
proximity of these mutations signifies that the carboxyterminus of the protein encoded by
exon 8 pJays an important role in the normal function of the galactokinase protein. It is
likely that the A384P substitution disrupts this function by inducing topological changes, as
noted by the secondary structural predictions.
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The fact that R68C and A384P were not detected among 100 norma1 chromosomes
suggests that these amino-acid substitutions Me the cause of the galat.tokinase deficiency
phenotype in patient 1.
The T288M substitution is the first reported mutation to occur in exon 6 of the
CALK! gene. This amino-acid change is located within the fourth galactokinase fingerprint
mmif whose function has yet to be characterized. The threonine residue at this position is
consenred in the galactokinase protein of 7 organisms, including the mouse. The nature of
the substitution (polar to nonpolar) also suggests that this amino acid change causes a
reduction of ga1actokinase activity by interfering with a criticaJ function provided by the
fourth fingerprint sequence.
The 2833delC deletion m exon 5 would produce a truncated non-functional

galactokinase protein that is significantly shorter than the wild-type enzyme. When coupled

with the T288M missense mutation, it is likely that galactokinase activity would be reduced
to levels conducive to the deficiency phenotype, as is the case in the biochemical
description of patient 2. The intronic 2149T~c transition also canied by this patient may
potentially effect the transcriptional processing of exon three of the CALK! gene by
interfering with a putative branchpoint motif consensus sequence (Rautmann &

Breathnach, 1985, Chiara et al., 1996). Similarly the 303A-+G transition found within the
promoter region of the S'UIR may also affect expression. However without functional
expression studies both these possibilities are unclear. Evidence will be presented in
Chapter 4 that these nucleotide changes are not a cause of reduced erythrocyte
galactokinase activity as the 2149T--+C transversion is shared, in the homozygous state, by
an individual with nonnal erythrocyte ga1actokinase activity. The same individual is also
heterozygous for the 303A-+Gtransition.
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The detection of the previously characterized P28T mutation in patient 3 suggests
that the incidence of this pmicular mutation may occur in groups other than the Roma
population. If in fact Patient 3 is of true Turkish extraction as reported, this finding may
signal the possibility that the P28T mutation may have a more widespread distribution
across populations in Europe than first thought. Supporting this, was the detection of the
P28T m1Jtation in eight patients belonging to geographically dispersed Gypsy groups
throughout Bulgaria, Hungary and Spain. Further analysis as to whether the P28T mutation
found in these patients is the same founder mutation commOn to the Vlax Roma or reflects
a recurrence of the substitution at the same codon, forms the basis for the investigation in

Chapter 5.

3.4.2 Nucleotide variations
It is likely that the non~disease associated nucleotide variations from the published
GALKJ sequence detected in this study reflect errors in the sequence deposited in the

Genbank database (Genbank accession' L76927). Support lor this claim comes from the
fact that the same nucleotides were also detected previously among both Caucasian and
Japanese samples (Asada et al., 1999). The current investigation has detected these base
changes among European/American, Afro-Hispanic and Turkish individuals, signaling that
it is likely that these differences are sequence errors rather than population-specific
polyrnorphisms. No information as to the ethnic origin of the individuals used in the

generation of the L76927 GALKI sequence has been provided (Bergsma et a!., 1996).
Further analysis using a more comprehensive c:ross~section of population groups would
rebuke or confinn definitively whether these changes are errors or represent true

polymorphism.

3.4.3 General discussion of mutation in the GALJ(l gene
A total of twenty GALKI mutations associated with the galactokinase deficiency
phenotype have been reported to-date (Stambolian et al., 1995; Asada et a!., 1999;
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Ko1htydjieva ct al., 1999; Kolosha ct a!., 2000). Except for two founder mutations, namely
P28T which occurs among the Vlax Roma (Kalaydjieva ct al., 1999) and Q382X found in
patients of Costa Rican/Europeom descent (Kolosha ct al., 2000), the remaining aberrations
are private mutations, confined w individual families. Similar to most individuals with
galactokinase deficiency described previously, two patients in this analysis were also found
to be compound heterozygotes, adding four novel molecular defects to the allelic
heterogeneity of CALK! mutations (Figure 3.23).
The lack of other changes in the coding sequence of the CALK I gene, the nature of
i.~~~-: dr·r:>r:ted sequence variants and their predicted effect on the protein, lead to the

suggestion that these arc disease~causing mutations. Including the mutations identified in
this analysis, the overall distribution to~date is 14 amino acid substitutions and 10
truncating mutations, with exons 1, 2 and 7 harbouring 13 of the known mutations. The
majority of missense mutations cluster in close proximity to the galactokinase signature
sequence in exon 1 and the second A TP~binding domain in exon 7, highlighting the
functional significance of these regions for the enzyme activity.
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Figure 3.23 Distribution of mutations in GALK1.

3.4.4 Fttturc Directions
\Vhile the idcntifical"ion of additional GALKJ mutations m individuals with
gabctokin.tsc def1ciency should ultimately contribute to understanding the functionally
important domains of the galactokinase protein, the rarity of the individual defects and the
compound heterozygous state of most patients, suggest that meaningful studies of
genotype/phenotype correlations in the affected individuals are not feasible.

It is the

founder mutations, in the homozygous and in the carrier state, that will allow such stucUes,
as well as research into the role of galactokinase deficiency as a factor predisposing to the
common presenile cataracts.
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CHAPTER 4 ANALYSIS OF GAIKl IN PATIENTS WITH THE ATYPICAL
PHENOTYPE
4.1 INTRODUCTION
The CALK! gene was analyzed in two patients sharing a common ethnic
background (Afro/Hispanic) and presenting with a rare, newly identified phenotype
characterized by increased blood galactose, lack of production of galactose-1-phosphate,

but no detectable reduction in erythrocyte galactokinase, galactose-1-phosphate uridyl
transferase or UDP galactose-4-epimerao;e activity. Due to the role that galactokinase plays

in the metabolism of galactose, it was considered that the newly identified phenotype may
result from a defect in the tissue specific expression of CALK!, in particular a liver form of

the enzyme. Because of the common ethnic background of the patients and the fact that

they share this rare phenotype, it was hypothesized that a disease-causing mutation in the
GALKI gene common to both patients, would be present in the homozygous form.
4.2 SUBJECTS

The study included two patients, who had been identified by newborn screening as
hypergalactosemic. The biochemical phenotype of these patients is summarized in Table
4.1. The two families are unaware of any relatedness, however both

ar.~

of Afro-Hispanic

descent. The aims of the study were explained to the families and infonned consent for
participation was obtained from the parents according to the ethical guidelines of the
institutions involved.
Table 4.1

Biochemical Findin~s of Study Sample
Patient

A•
lJo

Hypergalactosernia

+
+

Gai-1-P

Galactokinase

-vo

-ve

Normal
Nonnal

RBCActivi
G-1-P
mid~! transferase
Nonnal
Nonnal

UDPCE:lmerJ.Sc

Nanna!
Nonnal

• Dept of Pediatrics, Harvard University School of Medicine

66

4.3METHODS
DNA was extracted from whole venous blood

by the Genetic Service, Children's

Hospital and Depoutment of Pediatrics, Harvard Medical School, Boston, USA.
The coding regions of the galactokinase CALK! gene and flanking intronic
sequences were amplified according to protocols and conditions as described (Chapter 3,
Table 3.2). PCR primers for the GK1 5' untranslated region (5'UI'R) were designed from
the published CALK! sequence (Genbank Accession • L76927) as follows: forward primer
and

5' -CTGATGACCTCfCACAGCfGC-3'

5'

reverse

CTGTCTCAAAGCAGCCATCACG-3'. Due to errors in the published GK1 sequence
(Genbank Accession • L76927), amplification primers for the 3' VIR were chosen from
the sequence of Homo sapiens chromosome 17 clone RPll-474!111 (AC019214): forward
5'-GCTGTGCTTGTGAGGCACC-3'
CTTCCAAACTTGACCGCAcccr-3'.

and

reverse

5'-

PCR amplification was performed m a total

volume of 50 ~1, containing 20% of genomic DNA, 1x PCR Buffer, 1.5mM MgCI 2,
1.25mM dNTPs, 4% DMSO, 2mM of each primer and 0.5 U of Taq. Cycling conditions
included initial denaturation at 94°C for 5 minutes, followed by 35 cycles of 94°C for 30

sec, annealing at 63°C for 30 sec and extension at 72°C for 45 sec, and a final extension at
72°C for 7 minutes. All PCR products were cleaned using Qiagen purification colunms.
Cycle sequencing of GALKJ was performed using the ABI Prism Big Dye'"

Terminator Cycle Sequencing Rc~dy Reaction Kit. The products were run on the ABI
Prism 377 Automated DNA Analyzer.

software was used for sequence analysis.

The Sequence Navigator

(PE Biosystems)

Patients' sequence data were compared to

unaffected controls run in parallel and to the published GALK1 sequence.

Searches of

the public domain genomic databases were performed using the BLAST program
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(;waibble http:! /www.ncbi.nlm.nih.gov/BLAST/].

Computer modeling of predicted

protein structure was done with the PHDsec {Rost & Sander, 1994) software [available

http:/I dodo.cpmc.columbia.cdu/ predictprotein/submit_dcf.html].

4.4RESULTS

4.4.1 Sequerzce analysis of the GALJ(l gene
Analysis of the entire coding sequence, flanking intronic sequences and the 5' and 3'

untranslated regions of the two patients identified five nucleotide substitutions differing
from the wild-type GALKJ sequence. These changes are shown in Table 4.2.

Table 4.2
GALK1 Nucleotide Differences in Atypical Patients
Patient A

Genotype

7456C4-T

Location
5' UIR
Intron 2
Exon6
lntron 7

1556G->A

Exon2

Heterozygous

Nucleotide•
303A--_.G
2149T->C

7087G___.A

Patient B

Heterozygous

Homozygous
Heterozygous

Heterozygous

• Nucleotide numbering according to GenbankAccession' L76927

The A~G transition at nucleotide position 303 is located in the GALKJ 5' UI'R,
within the 250 bp putative eukaryotic polymerase II promoter region (Bergsma et al., 1996).
Patient A is heterozygous for this sequence variant.
Patient A is also heterozygous for a C---+T transition at position 7456 in intron 7.
This is in close proximity to the 5' end of exon 8 of the GALKI gene, however it is not
located within a recognized consensus branch splice site sequence or the splice acceptor
site. The 2149T-+C nucleotide change in intron 2 is located 34 bp upstream of the 5' end
of exon 3 and 3 bp upstream of a putative eukaryotic consensus branch point scquenct:,

YNRAY {Chiara et al., 1996; Rautmann & Breathnach, 1985). Patient A was homozygous
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for this intronic substitution. The same sequence variant was also found in the
heterozygous state in another patient, with typical galactokinase deficiency, where two
disease-causing mutations (f288M and 2833dclC) have been identified (Chapter 3, Section
3.4.2).
The only change found

tn

the codjng sequence of GALK1 in patient A, was the

G-)A transition at nucleotide position 7087 (Figure 4.1) which results in the substitution
of glutamine for arginine at codon 286 (R286Q) in exon 6 (Figure 4.2). Although arginine
and glutamine djffcr in terms of side-chain charge, both arc hydrophilic amjno acids
(Figure 4.3), suggesting that the substitution is unlikely to affect secondary protein
structure.

Indeed, secondary-structural analysis using the PHDsec algorithm (Rost &

Sander, 1994) predjcts structural identity and no interference with the helix formed by tills
fingerprint motif (Figure 4.4).

GGGGG

G

G

G

G

G

A

A

G A

G

1\

TT

T

T

C

C

N

G
A

GC

G

GC

C

G

A C

C

A C

G

G

GCC

G

C

C

(Genbank Accession #L76927)

Figure 4.1 7087G-)A transition causing a R286Q substitution in exon six.

Wildtype
Codon
Amino acid
Nucleotide

283
G
GGG

284
E
GAG

285
I
A1T

286
R
CGG

287
R
CGC

288
T
ACG

289
A
GCC

283
G
GGG

284
E
GAG

285
I
ATT

286
Q
CAG

287
R
CGC

288
T
ACG

289
A
GCC

290

Q
CAG

R286Q
Codon
Amino acid
Nucleotide

290

Q
CAG

Figure 4.2 Residue change at codon 286 caused by the 7087G-)A transition. Wildtype
arginine is replaced with glutamine .
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Figure 4.3 R286Q- molecular comparison between arginine and glutamine residues
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AA
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Galactokinase R286Q
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H H

280
A R H v v G E I Q R T
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J-1
A
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H
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Figure 4.4 Secondary·structure prediction for the wild-type exon six galactokinase
sequence and the R286Q missense mutation using the PHDsec algorithm. Q286 in
boldtype face. E - extended sheet (beta sheet); H - helix; L = loop. The prediction is
meaningful for all residues with an expected average correlation > .69.
This R286Q missense mutation occurs within the fourth, evolutionary conserved

galactokinase fingerprint sequence (RRARHWGEIRRTAQ).

However, a BLAST

homology search comparing published galactokinase sequences of diverse species revealed
that this particular position is highly variable: while an arginine residue occurs in the murine
and human galactok.inase, glut~unine is the common amino acid at position 286, found in 6

out of 20 galactokinases which share the fingerprint motif (Figure 4.5).
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Gab.ctokinase motif four
K R A R 1-I A v s
K R .\ R H V v T
K R v R Ill L T
K R v R Ill L T
K R v R II V L s
K R A K 1-1 I I s
R A K H V y s
K R A R H A v s
R A K H v y s
R A K H v y Q
E R A L H v y R
R R A K H A v y
K R A R H v v L
R A K H v y s
R R A R H v v G
R R A R H V v s
K R A R H A v F
K R A Q H V L E
K F F G y I v R
R L v R H V v T

Or anism
N Q R T L
N Q R v L
N A R T v
N A R T v
N A R T v
E N Q R v L
L R v L
E
E N Q R T I.
E A L R v L
E
L R v L
E
E
E
E
E
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E
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I R R T
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Figure 4.5 Galactokinase fingerprint motif four. Bold highlight showing amino acid
variation analogous to residue 286 of the hwnan galactokinase protein at which the R286Q
substitution is found. Glutamine (Q) occurs in six of the galactokinases that share the

fourth galactokinase fmgerprint motif. Motif alignment by SPRINT (available
hrtp://www.bioinf.man.ac.ukldbbrowser/sprint/).

The onlt difference found between GALKJ in patient Band the wild-type sequence
was a G~A transition at nucleotide 1556 in exon 2.

This change results in a silent

mutation at codon 63 (L63L).
Comparisons of the GALKJ sequence in both patients and unaffected controls with

the published wild-type sequence (Genbank Accession • L76927) revealed a number of
nucleotide discrepancies previously reported by Asada et a!. (1999) that were shared in all
samples analyzed. These changes include a 41SC--tT and 418C--tT in the S'UTR, a
694C--tT in intron I, as well as a 2130C--tG and 2132A--tC in intron 2 (Chapter 3, Table
3.4).

4.5 DISCUSSION
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The unique characteristics of this condition, namely a markedly increased blood
galactose concentration, bck of galactose-1-phosphate and normal RBC galactokinase
activity, pointed to a rare disorder of the first step of galat:tose metabolism. The metabolic
evidence of galactokinasc deficiency, together with the normal activity of this enzyme in
peripher.tl blood cells, suggested a defect in tissue-specific galactokinase expression. The

rarity of the disorder ;md the common ethnic background of the affected individuals
suggested a common molecular defect. This study was therefore based on the hypothesis
that the two patients wUl be homozygous for the same disease-causing founder mutation in
the galacrokinase gene GALKJ.

4.5.1 Sequence analysis
Approximately 3.1kb of the GALKJ sequence were investigated, including all
coding regions, at least 100 bp of the flanking intronic sequences and the 5' and 3' U1R
This analysis failed to reveal any sequence variants that are plausible disease-causing
mutations. Within the coding sequence, the 7087G~A transition identified in patient 1
resulted in the non-drastic glutamine for arginine substitution at a non-conserved position
in exon 6.

In fact, this substitution reverted to the glutamine residue which is more

common in the galactokinase protein of different species. These findings, together with
the lack of effect on secondaty structure predictions, lead to the conclusion that R286Q is a
polymorphism that is unlikely to c.-:.use the disease. The single exonic change found in
patient 2, was a silent mutation at codon 63, i.e. again a neutral polymorphism.
Patient 1 also displayed three additional nucleotide substitutions in the intronic
sequence of the GALKJ gene. The 7456C~T transition in intron 7 does not affect a
known consensus splice motif, nor does it seem to activate a cryptic splice site and thus
appears to be a polymorphic variant. The other two nucleotide substitutions, at positions
303 in the SUTR and 2149 in intron 2, could potentially affect the level of expression of
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CALK! or the splicing of the primary transcript. The 303A~G change occurs in the
putative polymerase II pmmoter sequence (Bergsma et al., 1996), whereas 2149T ____,C i~
located in close proximity to a putative eukaryotic branch point motif {Chiara ct al., 1996).
\'\1llle expression studies are needed to investigate the hypothetical effect of these changes
on CALK! expression, their likely role as neutral polymorphisms is supported by the fact
that the same intronic substitutions have also been found to occur in a patient with typical
galactokinase in whom both disease-causing mutations have been identified (Chapter 3,

Section 3.4.2).
The most significant finding of this analysis was the lack of similarity between the
two patients. Both were heterozygous for nudeotide variation in CALK! and none of the
nudeotide variants were shared between the two patients. The findings indicate that these
two individuals, presenting with the same rare phenotype and originating from the same
ethnic background, carry different copies of the known galactokinase gene. The results
provide strong evidence against a role of CALK! in this condition.

4.5.2 Other aberrations to galactose metabolism
Although it is likely that this investigation excluded CALK! as the responsible gene,
the possibility remains that both patients share an aberration in another gene involved in
galactose metabolism. Supporting this possibility is evidence pointing towards the existence
of multiple forms of the enzyme including both age-related and tissue differences in
galactokinase expression levels (Ng, Donne!, & Bergren, 1965; Shin-Buerhring, Beier, Tan,
Osang, & Schaub, 1977) and variation in kinetic and functional properties (Cuatrecasus &

Segal, 1965; Mathai & Beutler, 1967; M.1gnani eta!., 1982b). Perhaps the most compelling
evidence for multiple forms of the enzyme comes from clinical data of an adult who is
homozygous for a known deficiency-causing mutation yet has intermediate erytlu·ocyte

galactokinase activity analogous to a heterozygote carrier (Kalaydjicva et al., 1999). Whether
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this discrepancy and the reported differences in the properties of galactokinasc arc due to
the presence of two different genes or reflect post~translational modification of the same
protein remains to be characterized. Identifying the mechanism(s) responsible for these
observations may aid in detennining the cause of the persistently high levels of blood
galactose that is associated with this new phenot:yi.- :.
Alternatively, future directions for determining the genetic basis for this new
phenotype include an analysis of other genes or processes that may play a role in galactose

utilization. One likely candidate is the SLC2A2 gene (Genbank Accession ' 4557850)
which encodes a hepatic facilitative hexose transporter {GLUT~2). The cellular uptake of
galactose is made possible by the GLUf.2 transport mechanism capable of carrying both

glucose and galactose across the hepatocyte membrane (Burchell, 1994). The fact that such
receptors display different degrees of specificity for the two hexoses, suggests either
inherent differences in the binding sites vf the transport protein, or may reflect variation in

the efficiency of binding at the same site. Both pharmacological (Ibu & Shott, 1986) and
physiological (Fiete, Brownell, & Baenziger, 1983) evidence indicates that galactose uptake
at these receptors can be modulated, possibly signaling inherent differences in the substrate
binding domain of the transporter {W"u, Fritz, & Powers, 1998). Mutations to a galactose·

binding site would limit liver uptake, leading to an accumulation of galactose in the blod.

If the sugar was present in high concentrations, the erythrocyte capacity to successfully
phosphorylate galactose may become saturated, leading to further accumulation of
galactose and subsequent initiation of the galactitol pathway. The production of a
pathological level of galactitol would result due to the wide distribution of the galactose
reducing enzyme, aldose reductase, found in a number of tissue sources including the lens

of the eye (Segal & Beny, 1995). A defect to the hepatic galactose transport mechanism
may possibly lead to an increase in blood galactose analogous to the biochemical
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description of the patients in the currcm study. Both possibilities should be considered for
further ~malysis in detem1ining the molecular aberration responsible for this phenotype.
Other pathologies affecting galactose metabolism should also be considered. Two
reports Qakobs et a!., 1988; Budde, Gusek-Schneider, Junemann, Jansen, & Shin, 1999)
detail omother metabolic disorder affecting the galactose pathway called Shin-Jakob's
disease. In this condition, subjects present with increased blood galactitol levels and
cataracts without any identifiable defect to any of the three enzymes in the Leloir pathway.
Jakobs et al. (1988) suggest these findings may be explained by three possibilities including
an aberration to a fourth unknown galactose enzyme, a variant of a known enzyme or an
increase in activity of the enzyme, aldose reductase. The molecular defect underlying these
observations has yet to be elucidated.
Segai {1998) suggests that the hypergalactosemia seen m some galactosemic and
galactokinase-deficient sufferers, despite a restriction of galactose from the diet, may be
attributed to endogenous sources of g<~lactose. This source includes the recycling of UDPgalactose from cell membranes. If the enzymatic mechanism for this salvage process was
over-expressed, it would cause a rise in blood galactose levels that may overload the
functional capacity of galactokinase.

4.5.3 Conclusions
Although this analysis has excluded mutations in the known promoter region v.r:ithin
the SUIR of the GALKl gene as well as the entire coding regions, flanking intron regions
and the 3'UTR, functional expression studies and characterization of mRNA transcripts
from both patients should be carried out in the future. Such investigations may identify
differences in expression of galactokinase shared by these patients. These differences may
possibly reflect the use of different splicing mechanisms or alternatively reflect the use of
tissue-specific GALKl promoters not identified in our c11rrent knowledge of the gene.
Testing for mutations in the SLC2A2 gene, which encodes the hepatic glucose/galactose
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tr.msporter, or linkage analysis arc other strategies that should be used in future studies to
determine the cause of this phenotype.
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CHAPTERS

ANALYSIS OF THE ORIGINS, DISTRIBUTION AND

FREQUENCY OF A COMMON GALJ(l MUTATION CAUSING
GALACTOKINASE DEFICIENCY
5.1 INTRODUCTION
The P28T mutation has previously been identified as the common mutation causing

galactokinase deficiency in six Romani families from Bulgaria (Kalaydjieva et al., 1999).
Titese families originate from three socially distinct but genetically related groups; Kalderas,
Rudari and Thracian Tinkers, whose migratmy patterns can be traced back to the northern

part of the Balkans. Indeed the Vlax Roma, as they are collectively known, show a high
number of affected births, with incidence in the range of 1:1600 to 1:2500 birrhs and based
on the screening of 130 individuals, a predicted carrier rate of the P281' mutation, in the

vicinity of 4%-5%.
TI1e fact that the current investigation (Chapter 3, Section 3.3.3) has identified a
number of patients from Gypsy groups geographically dispersed throughout Europe and
socially and culturally distinct from the Vlax Roma, suggests that the distribution of the
P28T mutation is more widespread than first thought. Establishing that the P28T mutation

in these groups is shared common by descent and is not a recurrence of the same mutation
at the same codon, will provide infonnation into the genetic origins and relatedness
between such groups and will allow a study of the history of the mutation and the historical
demography of the affected groups. At the same time, the identification of populations at
high risk of infantile and perhaps presenile

blindne.~s

means that screening strategies and

early intervention can be utilized to prevent the progression to sight impainnent caused by
galactokinase deficiency in these groups.
Two strategies need to be employed to achieve this. 11lis first is establishing the
common origin of the P28T mutation. Previous haplotyping analysis in Bulgarian Romani
families has identified a conserved haplotype surrounding the P28T mutation (Kalaydjieva
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et al., 1999). The disease allele has been shown to be in strong linkage disequilibrium with

allele 2 of the marker Dl7Si839, located at a small physical distance to G!ILKI.
Identifying similar conserved regions of homozygosity will point towards a common origin
of the P28T mutation. Evidence of historical recombinations in the diverse Gypsy groups
will allow further studies of the history of the mutation.
Establishing carrier rates by screening unrelated individuals for the P28T mutation

will allow future prevention programs for infantile blindness such as newborn screening
and dietruy intervention to be designed, and their cost~efficiency estimated. Furthermore it

will allow future studies investigating the link to presenile cataracts

to be conducted, based

on the large numbers of carriers of the same mutation where other factors, eg. nutrition,
can be taken into account.

5.2 SUBJECTS

5.2.1 Haplotype analysis determining the origin of the P28T mutation

The study sample included 13 subjects (Table 5.1): six have been identified as homozygous
for the P28T mutation (Chapter 3, Section 3.3.3) and seven unaffected family members.
These patients derive from geographically dispersed regions throughout Europe including,

Turkey, Spain and Hungary and all but the Turkish patient report Gypsy origins. All were
small nuclear families, except for the consanguineous Spanish Gypsy kindred shown in
Figure 5.1. In additien, control P28T homozygous, heterozygous and unaffected

individuals derived from Bulgarian families were run in parallel for each of the markers.
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Table 5.1
Individuals with the P29T Mutation
Individual

P28T Genotype
Homozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Heterozygous
Homozygous
Heterozygous
Homozygous
Homozygous

Heterozygous
Heterozygous
Homozygous

Origin
Turkish
Turkish
Spanish Gypsy
Spanish Gypsy
Spanish Gypsy
Spanish Gypsy
Spanish Gypsy
Hungarian Gypsy
Hungarian Gypsy
Hungarian Gypsy

Hungarian Gypsy
Hungarian Gypsy
Hungarian Gypsy

a University Ollldren's Hospital, Zurich, S'l'.itzerland
Institut Bioquimica Clinica, Barcelona, Spain
' Dept. of P?.ediatrics, University Medical School, Szeged, Hungary
C cenotes kindred
b

5

Figure 5.1 Pedigree of consanguineous Spanish Gypsy family. Individuals whose DNA
was available for analysis are numbered.
5.2.2 Population Screening for the P28T mutation

The population distribution and frequency of the P28T mutation was analyzed in a
sample of 227 individuals from socially and geographically diverse Gypsy groups. 91 of
these belong to the Vlax Roma groups: 45 Rudari and 46 Lorn; 36 are derived from the
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Xoroxane Gypsies; and 39 belong to other Gypsy groups from Bulgaria. In addition, 55
Spanish Gypsies and 6 Lithuanian G;rpsies were also screened for the P28T mutation.
These data were combined with the results of previous screening carried out at the Centre
for Human Genetics, Edith Cowan University, of 144 individuals from Rudari, Lorn,

Kalderas and Xoroxane Gypsy groups (Table 5.2).

Table 5.2
Individuals Screened for the P28T Mutation

Previously
Population

screened

Vlax groups

n
135

Rudari
Lorn
Kalderas

Xoroxone
Others
Spanish

Lithuanian

This
Study
n
91

Total
n
226

79
13
43

45
46

124
59
43

9

36
39
55
6

45
39
55
6
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5.3 METHODS

5.3.1 Haplotype analysis
5.3.1.1 Micmsatdlitcmarkers
Six microsatellite markers (Table 5.4) spanning a 9cM region surrounding the

GALl(J gene were chosen from a selection of markers used in a previous study to

map the disease gene (Kalaydjieva et al., 1999). PCR amplification protocols and
conditions are detailed in Table 5.4. Each reaction consisted of 2011g of DNA,

0.2mM each primer, 0.25mM each c!NTP, optimal MgCI2 concentration (fable 5.4),
I x PCR buffer, 0.2U of Taq polymerase and dH,O to a final volume of 10~1.
Radioactive labeling was done through incorporation of

0.1~1

of u"P-dCTP

(GeneWorks cat •ADC-32U/L) in the product during PCR amplification.

Table 5.3
PCR Conditions and Protocols for Microsatellire Markers

Marker
01751797
01751602
01751864
0175929
0!751839
01751817

5.3.1.2

Size
183-193bp
197-207bp
183-209bp
217-229bp
237-245bp
183-209bp

PCR Conditions
1D 63oc ->55'{;
58"C !01 JS cycles
1D62" c --> 52•'C
1D 63"C ->55'{;
1D 63"C ->55'{;
62'{; for 35 cycles

Additives
1.5r<1M MgCI,
l.SnlM MgCI,
1.5mMMgCI,
1.5mMMgCI,
1.5mMMgCI2
l.OmMMgCI2

El~isanpolyacrylomiderr!

PCR products were electrophoresed on 6% polyacryhunide gels, prepared by
adding 420.4g of {7M) Urea and 150mL of 40% 19:1 acrylarnide/bisacrylamide to
SOOml of dH20. This solution was deionized for 30 minutes using mixed bead
resin. The solution was then filtered and lOOmL of lOx TBE buffer we5 C<dded and
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the final volume' made up to 1L with dH 20. Prior to pouring, 130).11 of 12% APS
(ammoniwn

persulphate)

and

130~1

of

TEMED

(N'N'N'N'' ' '

tetr-.m1Cthyl..>thylenediamine) were added to 60mL of polyacrylamide solution,
mixed, then injected between two cleaned and damped glass plates. Well formers
were inserted and the gels were left to set for 2 hours before fitting to the Hoefer
Poker Face II SE1600 Sequencing Series apparatus. Upper and lower chambers
were filled with 1 x TBE buffer and the gels were pre-warmed for 30 minutes at
1400V. The well former was removed and a loading comb inserted before each well
space was rinsed using a transfer pipette. lO)ll of formamide loading buffer (98%

formamide, !OmM NaOH, 0.1% bromophenol blue & 0.1% xylene cyanol) was
added to each PCR reaction and denatured for 5 minutes at 94 degrees C. Products
were placed on ice and 2:-tl of each sample was loaded into single lanes of the gel.
The gel was electrophoresed at 1400V for 2 hours. Plates were removed from the
apparatus and the outer glass plate was lifted off using a plastic wedge.
Approximately 200mL of fixer solution (10% methanol, 10% glacial acetic acid in
dH20) was poured over the gel 3 times over a duration of 10 minutes. The fixer

was then drained and a piece of chromatography paper was laid over the gel. The
paper and gel were lifted of the glass plate, covered with plastic wrap, and allowed
to dry on a Savant Slab Gel Dryer at 60 degrees C for I hour. Dried gels were

exposed on Cronex' Medical X-Ray film {Sterlin~ Diagnostic Imaging) in fdm
cassettes for approximately 14hrs at room temperature. The films were developed

on aAGFA' CURIX 60 developing machine.

5.3.1.3 Haplotype <UUdysis
Allele scoring was done manually, usmg a lighthox. Alleles were numbered
sequentially from top to bottom. To ensur~ compatibility of allele assignment with
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the previous study, several individuals from the original Bulgarian Gypsy families
(Kalaydjiev;t et a!., !999) were genotyped in parallel. Haplotypes were constructed

manually. In case parental information was missing (One of the Hungarian Gypsy
subjects), phasing was done by assigmnent of the most common haplotype to one
of the chromosomes.

53.2 Population screening for the P2BT mutation
The 563C-)o A transversion (P281) abolishes an Aval restriction site and thus a
PCR-based restriction assay can be used for screening purposes. A 450bp DNA
fragment spanning the region between nucleotides 358 and 808 in the GALKl
sequence (Genbank Accession ' L76927) was amplified from genomic DNA and
FfA cards by use of primers 5' -GGGGCGTCCGGGCGCGGGGC-3' and

s'-

GACAGGCTGTTCCCCACGT-3' . PCR volumes were made up to 201'1 and

consisted of 20ng of starting DNA for genomic samples, or a lmm x lmm section
of FfA card. In addition, the PCR mixture contained 1.25mM of MgCI,, 2mM of
each dNTPS, 1 x PCR buffer, 4% DMSO, O.SU of Taq polymerase and dH,O.

PCR conditions included initial denaturation at 94 degrees C for 5 minutes,
followed by 35 cycles of 94 degrees C for 30 seconds, 63 degrees C for 30 seconds
and 72 degrees C for 40 seconds. This was followed by an additional extension step

at 72 degrees C for 7 minutes. PCR products were sodium/ethanol precipitated as
described in Section 3.3.4 and resuspended in Sfll of dH,O. Products were cut with
0.31'1 of the restriction endonuclease, Ava! [10 OOOU/ml] (New England Biolabs
cat' R0152S), 1.51'1 of NE buffer, 1.51'1 of BSA and dH,O in a final volume of

12.5f.ll. Products were incubated at 37 degrees C for 3 hours before electrophoresis
upon 4% agarose/EtBr gel at 60V for 1 hour. Digests were visualized on a Hoefer
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Mighty Brightn' UV Illuminator and the image was recorded usmg a Kodak s
DC120 digital camera and Kodalt Digital ScicnceTM software.
Carrier frequency was determined by counting the number of affected alleles
detected and compared with carrier frequencies calculated from a similar screening
strategy carried out previously at the Centre For Human Genetics, E.C.U.

5.4 Results

5.4.1 Haplotype analysis
Haplotype amolysis revealed complete homozygosity for marker D17S!839 for mutant
chromosomes across Europe (Figure 5.2 & 5.3). Allele 2 of this marker was present in all
chromosomes with the P28T mutation and has previously been shown to be in strong
linkage disequilibrium with the P28T mutation among six Bulgarian Gypsy families
(Kalaydjieva et al., !999). The fact that the Hungarian Gypsy patients, Spanish Gypsy
patients and the Turkish patient are also homozygous for this allele in conjunction with
P28T, points towards a common founder mutation.
A highly conserved haplotype common to the haplotype seen in the Bulgarian Gypsy
families, was carried by 5 chromosomes in 4 Hungarian Gypsies and 1 Spanish Gypsy
(Figure 5.2). The alleles seen in the rest provides evidence of different historical
recombination which would be expected, given that the sample of patients analyzed
originate from dispersed groups.
Allele 2 of the D17S!839 marker was not found in any of the Bulgarian, Hungarian
and Turkish control individuals, not carrying the P28T mutation. This provides further
evidence that this particular allele is in strong linkage disequilibrium with the disease
mutation.
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5.4.2 Poprtlation screening and Carrier Frequency of P28T
The PCR~based Aval restriction assay of 227 individuals detected one homozygou;;
affected individual belonging to a Vlax Roma group and one heterozygous carrier from the

Spanish Gypsy group. Carrier frequencie> (Table 5.4) in both these populations were
calculated by the number of affected alleles detected, thus giving a carrier rate of 2.2% in

the Vlax Roma population and 1.8% in the Spanish Gypsy population.

The homozygous individual is of Rudari origin and when combined with previous
screening data, the carrier frequency within the Rudari group to date is 3.2%. As with
previous fmdings, no carriers of the P28T mutation were detected among the Lorn

population. Previously, carrier frequency in the Kalderas has been found at 4.6%. Although
individuals from this group were not available for screening in the current investigation, it
seems that both the Rudari a.1.d Kalderas groups are major contributors to the overall
carrier frequency of the P28T mutation seen in the Vlax Roma, which from the current
analysis stands at 2.7%. No carriers were detected in the Xoroxone group nor within the

small number of Lithuanian Gypsies analyzed.
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5.5 DISCUSSION

5.5.1 Haplotypes
It is evident that the P28T mutation detected in Bulgarian, Spanish and Hungarian

Gypsy patients as well as the Turkish patient is the founder mutation reported in 'lix
Bulgarian families (Kalaydjieva et a!., !999). The identification of a shared region of
homozygosity surrounding the D17Sl839 marker in all patients with the P28T mutation
signifies a common origin. The fact that allele 2 of the D17S1839 marker was not seen in

individuals without the P28T mutation also lends further support that the disease allele is in
strong linkage disequilibrium with this allele.
It is interesting to note that the haplotype analysis has revealed that the P28T
mutation carried by the Turkish patient, is in fact the same founder mutation common to

Bulgarian, Hungarian and Spanish Gypsy groups in the study. It is likely that the ethnicity
of this patient and mother is obscured perhaps to avoid the racial and social persecution
and prejudices historically aimed at the Gypsy population. The high degree of
polymorphisms in the haplotype pattern evident in this patient, as compared to other

patients, may reflect historical recombinations resulting from the divergence of Turkish
groups away from a common Gypsy origin or alternatively may indicate admixture.

5.5.2 Population screening and Carrier Frequency of P28T
The detection of a heterozygote carrier in the population screening of the Spanish
Gypsy group, combined with the findings of the common founder mutation in patients of
Spanish and Hungarian Gypsy descent, highlights the widespread distribution of the P28T
allele. Tbis infonnation is not only important for the development of intervention
strategies targeting groups at risk of infantile and presenile blindness but also paves the way
for anthropological studies perhaps investigating the historical origins and diversification of
the many Gypsy groups.
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5.53 Conclusions and future directions
Both the detection of a heterozygot< carrier through screening of the Spanish Gypsy
population ;md the haplotype analysis of a Spanish Gypsy kindred suggest that the
incidence of the P28T mutation is widespread throughout Europe. Additional dat:.\ need to
be collected for the Spanish Gypsy population, before newborn screening is initiated. For

the time being, galactokinase deficiency should be considered in any patient of Gypsy
ethnicity with infantile cataracts and the P28T mutation provides an easy test. The

mutation test can be incorporated in the existing newborn screening in Hungary and

Bulgaria to replace the current lengthy procedure of diagnosing galactokinase deficiency by

metabolic and enzyme assays. Finally, large numbers of adult carriers can be identified by
either cascade testing in the families of affected children or by random population
screening. These subjects can then be studied funher to clarify the proposed link between

panial galactokinase deficiency and presenile cataracts.
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CHAPTER6

SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS

Conclusive infonnation regarding the molecular basis of galactokinase deficiency and
galactose metabolism is far from complete. The mechz.nisms underlying the discrcpancie!;
that exist between galactokinase activity and properties in relation to factors such as age,

tissue and allelic heterogeneity, are still unclear. Atypical clinical observations further
confound existing ideas about the function and role of galactokinase in galactose

metabolism. This is evident from the clinical descriptions provided in Chapter 4 of patients
with a rare galactokinase deficiency phenotype, characterized by increased blood galactose
levels, yet normal enzyme activity in RBCs, as well as the observations of an adult with

intermediate galactokinase activity despite being homozygous for a known deficiency·
causing mutation (Kalaydjieva et al., 1999). Perhaps these observations signal the existence

of mulciple forms of the enzyme or even multiple mechanisms and/or pathways of
galactose metabolism. Whether these are the result of an enzyme encoded by separate
genes or reflect differences in post-translational modifications and/or alternative regulation
of expression of the same gene product, remain to be clarified. Furore steps which need to
be taken to address these possibilities, include extensive mRNA comparisons,
enzymological characterization, or haplotype analysis. The outcomes from these
investigations may not only complete our nnderstanding of galactose metabolism but also
benefit the treatment of patients. For instance, recognizing heterogeneity in expression or

activity as a function of age would have implications as to the extent and duration of
dietruy intervention in affected individuals.
The current investigation has added 4 novel molecular defects: R68C, T288M,
A384P and 2833delC to the allelic heterogeneity of GAL!(J mutations. Despite the lack of
expression analysis in this study, it is likely these are disease-causing mutations due to the
nature of the mutations, the fact that they occur in conserved residues and did not occur
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among 100 normal chromosomes. While the identification of additional GALKJ mutations
in individuals with galactokinase deficiency should ultimately contribute to understanding
the functionally important domains of the galactokinase protein and the molecular basis of
the disorder, the rarity of the individual defects and the compound heterozygous state of
most patients, suggest that meaningful studies of genotype/phenotype correlations in the
affected individuals are not feasible. It is the founder mutations, in the homozygous and in
the carrier state, that will allow such studies, as well as research into the role of partial
galactokinase activity as a factor predisposing to presenile cataracts.
The findings of a common origin, carrier frequency and distribution of one such
founder mutation P28T, amongst dispersed Gypsy populations, have impl.;cations for the
development of newborn screening programs and dietaJY intervention to prevent the
incidence of infantile blindness in susceptible groups. The results also pave the way for the
future identification of large sample numbers of both homozygotes and carriers in order
for extensive genotype/phenotype correlations to be investigated. This will ultimately
contribute to the complete characterization of the role galactokinase plays in galactose

metabolism and the molecular basis of the deficiency phenotype.
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Galactoklnase deficiency is an inborn error of galactose metabolism whose major clinical
manifestation is the development of cataracts during the first months of life. Only 20
mutations have been reported to date and understanding or the functionally important
domains of the galactokinase protein is still limited. Here we report four novel mutations in
GALKJ that were identified in two unrelated patients with galactokinase deficiency. Three
of these were amino acid substitutions: t569C---)T in exon 2 {R68C); 7093C~T in exon 6
(T288i\f) and 7538G~C in exon 8 {A384P). In addition, ~single base-pair deletion was
found in ex on 5 (2833deiC), predkted to result in a shift of the reading frame and a
premature termination codon at position 263. Some differences with the GALKI sequence
deposited in Genbank are also reported.{~_:. 2000 Wiley-Liss, Inc.

KEY WORDS: Galactokinase deficiency, CALK I, galactosemia, galactose metabolism, cataracts

INTRODUCTION
Galactokinase (E.C.2. 7.1.6) catalyses the conversion of galactose to galactosc-1-phosphatc, the first step of the
Lcloir metabolic pathway through which galactose enters glycolysis. Galactokinase deficiency (MIM# 230200) is
an autosomal-recessive disorder whose metabolic consequences include a dramatic elevation of blood galactose
concentration, galactosuria, lack of or greatly diminished production of galactosc-1-phospatc and activation of an
alternative pathway of galactose metabolism, leading to the production of galactitol (Gitzelmann. 1965). The
clinical phenotype is confined to the development of cataracts in affected infants during the first months or even
weeks of life, as a result of the accumulation of galactitol in the lens of the eye and subsequent osmotic disruption
of the lens fibers. Galactokinase deficiency can be diagnosed in the newborn period by hypergalactosemin
screening and its consequences arc fully preventable by galactose-restricted diet. II has also been suggested that
partial deficiency of galactokinase activity in heterozygous carriers may contribute to susceptibility to presenile
cataracts (Stambolian et al., 1986).
Received 29 September 2000; Revised manuscript accepted 13 November 2000.
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The gen.: encmiing human galactokinase, G.·ILKI, was cloned in 1')!)5 and mapped by in-.1i/11 hybridization to
the long ann ~1f chromosome 17 (Stambolian ct al., llJ!JS). l.inkagc analysis in affected Htmilics and radiation
hybrid mapping have subsequwtly been used to refine its po~ition to a I eM region on 17q24 (Kalaydjicva ct a!.,
19 1)9). The );:l'llC spans approximately 7.3kb of genomic DNA and consi~t~ of eight cxuns cnwding a protein of
3')2 amino acid residues (Bergsma et al., 1996). Apart from two putative AlP-binding motifs cncmlcd hy ex on~ 3
anll7, understanding oft he structure oft he galactokinasc protein and its functionally important domain~ i~ still
poor, partly due to the limited number of studies addressing the genetic basi~ of galactokinasc deficiency.
Here we report four novel probable disease-causing mutations identified in two unrelated Cauca~ian individuah
with galactokinasc dcticiency.

METIIODS
The affected individuals, one female and one male now aged 4 and 17 years, were detected a-; hypergalacto~cmic by
newborn screening. Ga\actokinase deficiency(< 5% of the lower limit of the nonnal range) wa~ con finned by enzyme
activity measurements in red hlood cc11s (RBC). The patients arc on galactosc-rc.\tricted diet and arc symptom-free.
The search for mutations in GA.LK I was pcrfonncd on genomic DNA, by PCR amplification and direct sequencing of
both strands of the 5' and 3' UTR. a11 coding regions of the gene and at least 100 bp of flanking intronic sequences. The
primers used for the analysis of the untranslatcd regions were: for the 5'UTR 5'-CTGATGACCTCTCACAGCTGC-3' and
5'-CTGTCTCAAAGCAGCCATCACG-3', and for the 3'UTR 5-GCTGTGCTTGTGAGGCACC-3' and 5'- CTICCAAA
CTTGACCGCACCCT-3'. Exons and flanking intronic sequences were analysed as described (Kalaydjicva et al., \999).
PCR reactions were made up to SO )11 and consisted of 2011g of genomic DNA, Jx PCR Buffer, l.SmM ~gC1 2 , 1.2SmM
dNTPs, 4% DMSO, 2mM of each primer and 0.5 U ofTaq. Cycling conditions included initial denaturation at 94°C for 5
minutes, 35 cycles of94°C for 30 sec, 63°C for 30 sec and 72°C for 45 sec, and final extension at 72°C for 7 minutes.
Sequencing was performed using the ABI Prism Big DyeTM Tenninator Cycle Sequencing Ready Reaction Kit and the
reactions were run on an ABI Prism 377 automated DNA Analyzer. Data processing was done using Sequence
NavigatorTM (PE Biosystems), where the patient sequences were compared to unaffected controls run in parallel, and to the
published GALKJ sequence (Gcnbank Accession# L76927). Searches of the public domain genomic databases were
performed using the BLAST program [available at http://www.ncbi.nlm.nih.gov/ BLAST/]. Computer modeling of the
predicted structure of the mutant protein was done with the PHDsec software (Rost & Sander, 1994) available at
[http://dodo.cpmc.eolumbia.edu/ predictprotcinlsubmit_def.html].
A panel of 50 unrelated adult healthy Caucasian controls was tested for the presence of the putative disease-causing
mutations by PCR-based restriction assays.
The nucleotide numbering provided below is according to Genbank Accession# L76927.
RESULTS

Both individuals were found to be compound heterozygotes for different molecular defects, none of which has
been described previously: patient I presented with two missense mutations, R68C and A3R4P, and patient 2
carried one missense, T288M, and one frameshift mutation, 2833delC.

~
A 1569C~T transition in cxon 2 is predicted to result in the replacement of arginine by cysteine at codon 68.
R68C is the fourth mutation described in exon 2, the remaining three being truncating mutations (Stambolian et al.,
1995; Kolosha et al., 2000). The arginine residue at this position is strictly conserved in the galactokinasc protein
of over twenty different species checked, including the mouse. The mutation is a drastic change from a charged to
an uncharged amino acid residue with a sulfhydryl side-chain, however the computer predictions did not suggest
significant alterations in the secondary structure of the mutant protein. The 1569C~T transition creates an Alw Nl
restriction site. The PCR-bascd restriction assay, used as a screening test, failed to detect the mutation among 100
control chromosomes.
A384P

The 75380-R: transversion found in ex on 8 leads to the substitution of proline for alanine at position 3 84.
A384P is located 8 amino acid residues upstream of the carboxyl terminus of the protein and is the second reported
mutation in cxon 8, after Q382X (Kolosha ct al., 2000), suggesting that the carboxytcrminal part of the protein is
essential for galactokinase function. Alanine at this position is not highly conserved, it is present only in the two
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m:ttntn>llian gal>~ctnkinasc~ charac:criscd so far, human :.~nd moust', and se4uencc similarity is found in the prokins
of.so:ven additional species. The substitution nfpro!ine !i>r :tll111ine is likely to inUuce ~igni!icant topolo~;ical
changes, as predicted by the secondary structural analysis. The helix formed hetwccn the J-"37X and A3H4 residues
in the wild-type protein is abolisho:d by the mutation, which abolcaUs to an extension oft he beta sheet and cause~
loop fom1ation by >Hijaeent residues (Figure l ). The mutation abolishes a Ahv I restriction site. The restriction
assay !:tiled to detect AJ4NI' amon~ the 50 cnntml indivitluals.

Galactokinase, wild-t~·pe sequence
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Figure I Secondary-structure prediction for the wild-type exon eight galactokinase sequence and the
A:84P missense mutation using the PHDsec algorithm. P384 in boldtype face. E "' extended sheet
(beta sheet); H = helix: L "' loop. The prediction is meaningful for all residue> with an expected
average correlation> .69.

illftM

A 7093C--+T transition causes the substitution of methionine for threonine at codon 288. T288M i~ the first
mutation identified in cxon 6 of GALKI. encoding a conserved galactokinase fingerprint motif whose function is
currently unknown. As shown by the sequence alignment of this galactokinase motif (Figure 2). the threonine
residue at position 288 is conserved in nine out of twenty galactokinases. The mutation results in the replacement
of a polar amino acid residue by a nonpolar with a sulfur-containing sidechain. Secondary structuml predictions
are inconclusive. The mutation was tested in the panel of control individuals using a restriction assay (Nla Ill site
abolished by the mutation). It was not found among 100 normal chromosomes.

2833deiC
A single base-pair deletion, 2833de\C, was found in exon 5, where one missense and another truncating
mutation have been reported previously (A..<iada ct a\., 1999; Kolosha et al., 2000). Th~ 2833dc!C mutation is
predicted to result in a frameshifl and a premature termination signal at codon 263, leading to a protein that is 130
amino acids shorter than the wild-type enzyme. The presence of the deletion was independently confimted by
single strand conformational polymorphism (SSCP) and heteroduplcx (HDA) analysis.
In addition, we have detected a number of differences to the sequence published under Genbank Accession#
L 76927 (Table 1). They were found in both affected individuals and unaffected controls (n"'9) of Caucasian and
Afro/Hispanic descent in the present study, as we11 as in the Japanese and Caucasian individuals reported by Asada et al.
(1999).

Table t. Nucleotide Differences from Published GALKI Sequence GenBank Accession# L 76927
Region
Position
Nucleotide
Nucleotide
Nucleotide
(L76927)
(L76927)
(this study) n=9
(Asada ct ill\999) n=7
415
C
T
T
5'UTR
S'UTR
418
C
T
T
694
C
T
T
Intron I
lntron 2
2149
C
G
G

4

lluntt'r t'f •1.

lntmn2

~

151

A

('
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IHSCUSSION
lh~ incidence ~1f galactokinase delicicncy, as reported hy newborn .~crc!.'ning programs in Europe, the United
States and Japan, mnges between I: 150,000 and I: l ,000,000 (Levy, 19HO; Gitzclmann & llanscn, 19HO). The low
frequency of th~.-• disorder has imposed limitations on research into the genetic cuuscs of gulactokinasc deficiency,
resulting in a small number of reported mutations in CALK 1. Moreover, the small number of definite carriers that
can be identified by mutation dctcctior, precludes studies addressing the proposed role ofpanial galactokinasc
deficiency in the development of the common fonns of presenile cataracts.
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Species
Srrepromyces lividan.~
Haemophilus injluenure
Escherichia coli
Bacteriophage lambda
Salmonella typhimurium
Actinobaci flus pleuropnewnoniae
Saccharomyces cerevisiae
Lactobacillus he/veticus
Kluyveromyces lactis
Candida a/bicans
Candida parapsi/osis
Bacillus subtilis
Streprococcus thermophilus
Sacdwromvces cerevisiae (CAL3)
Homo sapiens
Mus musculus
Lactobacillus casei
Thermotoga neapolitana
Pyrococcus lwrikoshii
Streptom)'Ces fil'idans

Figure 2. Galactokinase fingerprint motif four. Bold highlight shows amino acid variation
analogous to residue 288 of the human galactokinase protein at which the T288M substitution is
found. Threonine at this residue is conserved in 9 of 20 organisms. Methionine at this residue is not
shared by any of the galactokinases that share the fourth galactokinasc fingerprint motif. Motif
alignment by SPRINT (available at hnp:l/li'\'_-· .v.bioinf.man.ac.ukl dbbrowser/sprintl).

A total of twenty GALKI mutationr associated with the galactokina~c deficiency phenotype have been
identified to-date (Stambolian ct al., 1995; Asada et al., 1999; Ka!aydjieva ct a!., 1999; Kolosha ct al., 2000).
Except for two founder mutations, namely P28T which occurs among the Vlax Roma (Kalaydjicva et al., !999)
and Q382X found in patients of Costa Rican!Europcan descent (Kolosha ct al., 2000), the remaining aberrations
are private mutations, confined to individual families. Similar to most individuals with galactokinasc deficiency
described previously, our patients were also found to be compound hctcrozygotes, adding four novel molecular
defects to the allelic heterogeneity of GALK1 mutations. The lack of other changes in the CALK I gene, the nature
of the detected sequence variants and their predicted effect on the protein, lead us to suggest that these are diseasecausing mutations. Including the mutations identified in this study, the overall distribution to-date is 14 amino acid
substitutions and 10 truncating mutations, with exons 1, 2 and 7 harbouring 13 of the known mutations. The
majority of missense mutations cluster in close proximity to the galactokinasc signature sequence in cxon land the
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second ATP-bimling domain in cxun 7, highlighting the functional ~ignificancc ofthc~c region~ for the crv:ymc
activity.
While the iJcntilkation of <ultlitional GALK I mutations in individuab with galactokinase dclkicncy ~huuld
ultimatc\y contribute to understanding the functionally important domains of the galactokina~c rrotcin, the rarity
of the individual defects and !he compound heterozygous slate of most patient.~. suggc.~t that meaningful .~ludic~ of
genotype/phenotype correlations in the affected individuals arc not fi:asiblc. It i~ the fi:JUndcr mutation~. in the
homozygous and in the carrier state, that will allow such ~tuJics, as well as research into the role of galactokina~e
detidency as a Htctor predisposing to the common presenile cataracts.
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